[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$foUDJ2VwkiYeytndgjNoxqJC5quPxz_C-C3YcFNnSdm4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":85,"rows":92},"Peking University Third Hospital",[4],715,false,194,11,664223,74,554,[14,17,20,22,24,27,29,32],{"name":15,"count":16},"Amyotrophic Lateral Sclerosis",18,{"name":18,"count":19},"Anterior Cruciate Ligament Injuries",14,{"name":21,"count":9},"Chronic Obstructive Pulmonary Disease",{"name":23,"count":9},"Anterior Cruciate Ligament Rupture",{"name":25,"count":26},"Dry Eye",8,{"name":28,"count":26},"Lumbar Spinal Stenosis",{"name":30,"count":31},"Radiotherapy",7,{"name":33,"count":31},"Stroke",[35,40,45,50,55,60,65,70,75,80],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04595162","A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL","2023-12-15","GC019F",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05411809","The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer","2024-06-15","drug adjuvant therapy",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT04834544","A Study of Maintenance DCVAC\u002FOvCa After First-line Chemotherapy Added Standard of Care","2024-10-20","DCVAC\u002FOvCa",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06062576","Clinical Observation and Mechanism Study of Yunnan Baiyao in Different Stages of Diabetic Foot","2024-12-31","Yunnan Baiyao",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06062589","AK104 Combined With I-125 Brachytherapy for Recurrent or Metastatic Cervical Cancer","2025-01-11","AK104",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT05924373","Human Dental Pulp Mesenchymal Stem Cells for the Treatment of Chronic Periodontitis Patients","2025-03-07","Human Dental Fulp Stem Cells",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06645197","An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis","2025-04-15","SNUG01",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT06522542","Gastric Cancer Complicated With Bleeding","2025-07-31","systematic therapy",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06608992","Evaluation of the Effect of SURGICEL® Powder in TKA","2025-08","SURGICEL® Powder",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT06876675","LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer","2025-09","Lorlatinib",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,142,186,221,251,269,294,312,337,355,381,402,430,448,470,496,522,540,567,592,616,640,668,691,735,757,783,804,841,878,905,923,949,967,995,1013,1038,1062,1080,1102,1129,1154,1172,1196,1222,1250,1268,1286,1311,1336,1356,1380,1409,1436,1461,1479,1503,1528,1555,1573,1591,1625,1654,1672,1692,1715,1738,1761,1788,1806,1828,1855,1873,1898,1916,1949,1971,1998,2016,2042,2060,2084,2102,2128,2154,2183,2201,2219,2237,2255,2273,2291,2309,2334,2358,2384,2410,2428,2451,2475,2499,2517,2541,2568,2593,2618,2636,2660,2688,2713,2747,2773,2791,2814,2839,2857,2880,2898,2924,2942,2966,2990,3008,3032,3050,3075,3093,3116,3142,3160,3189,3212,3230,3254,3276,3300,3318,3340,3364,3389,3414,3432,3454,3476,3494,3519,3537,3561,3579,3604,3630,3648,3672,3695,3713,3746,3777,3814,3837,3863,3890,3908,3926,3951,3975,3998,4022,4049,4075,4099,4125,4150,4176,4204,4229,4247,4270,4294,4318,4345,4368,4394,4419,4437,4455,4480,4498,4523,4545,4566,4591,4617,4643,4661,4684,4708,4732,4750,4775,4799,4825,4843,4868,4893,4911,4935,4961,4984,5008],{"intervention":54,"totalTrials":94,"cells":95},3,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":127},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":126,"soonestReadout":53},[107,119],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},"NCT06197412","Multi-center Clinical Observation and Mechanism Study of Yunnan Baiyao in Different Stages of Diabetic Foot Ulcer","RECRUITING",[90],"2025-12-31","2026-03-31","2023-12-01",100,[117],"Diabetic Foot Ulcer Treatment",[54],{"nctId":51,"briefTitle":52,"status":110,"phases":120,"primaryCompletion":53,"completion":121,"start":114,"enrollment":115,"conditions":122,"interventions":125},[90],"2025-06-30",[123,124],"Diabetic Foot","Therapeutics",[54],2,{"trials":128,"activeCount":98},[129],{"nctId":130,"briefTitle":131,"status":132,"phases":133,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":140},"NCT05765747","Effectiveness of Yunnan Baiyao in Improving Fracture Pain","UNKNOWN",[91],"2023-12-31","2024-06-01","2023-04-01",58,[139],"Distal Radius Fracture",[54,141],"Celecoxib 200mg",{"intervention":143,"totalTrials":126,"cells":144},"Metformin",{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":149,"PHASE3":151,"PHASE4":153,"NA":170},{"trials":146,"activeCount":98},[],{"trials":148,"activeCount":98},[],{"trials":150,"activeCount":98},[],{"trials":152,"activeCount":98},[],{"trials":154,"activeCount":169,"soonestReadout":159},[155],{"nctId":156,"briefTitle":157,"status":110,"phases":158,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":167},"NCT06742710","Liraglutide Treatment in Obese Infertile PCOS Women",[90],"2029-05-30","2029-12-31","2025-05-22",890,[164,165,166],"PCOS","Obesity","Infertility",[168,143],"Liraglutide and metformin",1,{"trials":171,"activeCount":169,"soonestReadout":177},[172],{"nctId":173,"briefTitle":174,"status":175,"phases":176,"primaryCompletion":177,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":184},"NCT06775093","Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity","NOT_YET_RECRUITING",[91],"2026-12-31","2027-12-31","2025-03-01",392,[182,165,183],"Polycystic Ovary Syndrome","Infertility, Female",[185,143],"GLP-1 receptor agonist",{"intervention":187,"totalTrials":126,"cells":188},"Tetrandrine",{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":197,"NA":219},{"trials":190,"activeCount":98},[],{"trials":192,"activeCount":98},[],{"trials":194,"activeCount":98},[],{"trials":196,"activeCount":98},[],{"trials":198,"activeCount":169,"soonestReadout":203},[199,210],{"nctId":200,"briefTitle":201,"status":110,"phases":202,"primaryCompletion":203,"completion":204,"start":205,"enrollment":115,"conditions":206,"interventions":209},"NCT07319598","A Study to Test Tetrandrine Tablets for Connective Tissue Disease-Related Lung Disease",[90],"2026-10-15","2027-01-01","2023-11-02",[207,208],"Interstitial Lung Disease (ILD)","Connective Tissue Disease-associated Interstitial Lung Disease",[187],{"nctId":211,"briefTitle":212,"status":213,"phases":214,"primaryCompletion":215,"completion":215,"start":134,"enrollment":98,"conditions":216,"interventions":218},"NCT05697029","Tetrandrine Tablets Used in Hospitalized Adults With COVID-19","WITHDRAWN",[90],"2025-12-12",[217],"COVID-19",[187],{"trials":220,"activeCount":98},[],{"intervention":222,"totalTrials":169,"cells":223},"allogeneic platelet plasma",{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":230,"PHASE4":232,"NA":249},{"trials":225,"activeCount":98},[],{"trials":227,"activeCount":98},[],{"trials":229,"activeCount":98},[],{"trials":231,"activeCount":98},[],{"trials":233,"activeCount":169,"soonestReadout":238},[234],{"nctId":235,"briefTitle":236,"status":175,"phases":237,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":247},"NCT07020559","Allogeneic vs Autologous PRP for Diabetic Wounds in Renal Dysfunction: a Randomized Controlled Trial",[90],"2027-12","2028-05","2026-04",56,[243,244,245,246],"Diabetic Wounds","Platelet Rich Plasma","Allogeneic Blood Transfusions","Renal Dysfunction",[222,248],"autologous platelet plasma",{"trials":250,"activeCount":98},[],{"intervention":248,"totalTrials":169,"cells":252},{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":261,"NA":267},{"trials":254,"activeCount":98},[],{"trials":256,"activeCount":98},[],{"trials":258,"activeCount":98},[],{"trials":260,"activeCount":98},[],{"trials":262,"activeCount":169,"soonestReadout":238},[263],{"nctId":235,"briefTitle":236,"status":175,"phases":264,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":265,"interventions":266},[90],[243,244,245,246],[222,248],{"trials":268,"activeCount":98},[],{"intervention":270,"totalTrials":169,"cells":271},"FB1006",{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":280,"NA":292},{"trials":273,"activeCount":98},[],{"trials":275,"activeCount":98},[],{"trials":277,"activeCount":98},[],{"trials":279,"activeCount":98},[],{"trials":281,"activeCount":169,"soonestReadout":286},[282],{"nctId":283,"briefTitle":284,"status":110,"phases":285,"primaryCompletion":286,"completion":286,"start":287,"enrollment":288,"conditions":289,"interventions":291},"NCT05923905","Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients",[90],"2027-09-30","2023-01-18",64,[290],"Sporadic and Familial Amyotrophic Lateral Sclerosis",[270],{"trials":293,"activeCount":98},[],{"intervention":168,"totalTrials":169,"cells":295},{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":302,"PHASE4":304,"NA":310},{"trials":297,"activeCount":98},[],{"trials":299,"activeCount":98},[],{"trials":301,"activeCount":98},[],{"trials":303,"activeCount":98},[],{"trials":305,"activeCount":169,"soonestReadout":159},[306],{"nctId":156,"briefTitle":157,"status":110,"phases":307,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":308,"interventions":309},[90],[164,165,166],[168,143],{"trials":311,"activeCount":98},[],{"intervention":313,"totalTrials":169,"cells":314},"Brivudine",{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":321,"PHASE4":323,"NA":335},{"trials":316,"activeCount":98},[],{"trials":318,"activeCount":98},[],{"trials":320,"activeCount":98},[],{"trials":322,"activeCount":98},[],{"trials":324,"activeCount":169,"soonestReadout":177},[325],{"nctId":326,"briefTitle":327,"status":110,"phases":328,"primaryCompletion":177,"completion":178,"start":329,"enrollment":330,"conditions":331,"interventions":333},"NCT07099157","Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster",[90],"2025-08-25",140,[332],"Herpes Zoster",[313,334],"Famciclovir",{"trials":336,"activeCount":98},[],{"intervention":334,"totalTrials":169,"cells":338},{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":345,"PHASE4":347,"NA":353},{"trials":340,"activeCount":98},[],{"trials":342,"activeCount":98},[],{"trials":344,"activeCount":98},[],{"trials":346,"activeCount":98},[],{"trials":348,"activeCount":169,"soonestReadout":177},[349],{"nctId":326,"briefTitle":327,"status":110,"phases":350,"primaryCompletion":177,"completion":178,"start":329,"enrollment":330,"conditions":351,"interventions":352},[90],[332],[313,334],{"trials":354,"activeCount":98},[],{"intervention":356,"totalTrials":169,"cells":357},"Telitacicept",{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":366,"NA":379},{"trials":359,"activeCount":98},[],{"trials":361,"activeCount":98},[],{"trials":363,"activeCount":98},[],{"trials":365,"activeCount":98},[],{"trials":367,"activeCount":169,"soonestReadout":372},[368],{"nctId":369,"briefTitle":370,"status":110,"phases":371,"primaryCompletion":372,"completion":373,"start":374,"enrollment":375,"conditions":376,"interventions":378},"NCT06546540","The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis",[90],"2025-12-10","2026-03-30","2024-06-08",20,[377],"Systemic Sclerosis",[356],{"trials":380,"activeCount":98},[],{"intervention":79,"totalTrials":169,"cells":382},{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":389,"PHASE4":391,"NA":400},{"trials":384,"activeCount":98},[],{"trials":386,"activeCount":98},[],{"trials":388,"activeCount":98},[],{"trials":390,"activeCount":98},[],{"trials":392,"activeCount":169,"soonestReadout":78},[393],{"nctId":76,"briefTitle":77,"status":110,"phases":394,"primaryCompletion":78,"completion":83,"start":395,"enrollment":396,"conditions":397,"interventions":399},[90],"2024-09-28",112,[398],"Knee Osteoarthritis",[79],{"trials":401,"activeCount":98},[],{"intervention":403,"totalTrials":169,"cells":404},"Glofitamab",{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":424,"PHASE4":426,"NA":428},{"trials":406,"activeCount":98},[],{"trials":408,"activeCount":98},[],{"trials":410,"activeCount":169,"soonestReadout":415},[411],{"nctId":412,"briefTitle":413,"status":110,"phases":414,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":419,"interventions":422},"NCT07460362","Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma",[88],"2027-12-30","2029-12-30","2025-08-11",43,[420,421],"MCL","Relapsed or Refractory Mantle Cell Lymphoma (MCL)",[403,423],"Lenalidomide",{"trials":425,"activeCount":98},[],{"trials":427,"activeCount":98},[],{"trials":429,"activeCount":98},[],{"intervention":423,"totalTrials":169,"cells":431},{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":442,"PHASE4":444,"NA":446},{"trials":433,"activeCount":98},[],{"trials":435,"activeCount":98},[],{"trials":437,"activeCount":169,"soonestReadout":415},[438],{"nctId":412,"briefTitle":413,"status":110,"phases":439,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":440,"interventions":441},[88],[420,421],[403,423],{"trials":443,"activeCount":98},[],{"trials":445,"activeCount":98},[],{"trials":447,"activeCount":98},[],{"intervention":64,"totalTrials":169,"cells":449},{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":464,"PHASE4":466,"NA":468},{"trials":451,"activeCount":98},[],{"trials":453,"activeCount":98},[],{"trials":455,"activeCount":169,"soonestReadout":63},[456],{"nctId":61,"briefTitle":62,"status":110,"phases":457,"primaryCompletion":63,"completion":458,"start":459,"enrollment":460,"conditions":461,"interventions":463},[88],"2026-09-30","2023-11-27",204,[462],"Periodontitis",[64],{"trials":465,"activeCount":98},[],{"trials":467,"activeCount":98},[],{"trials":469,"activeCount":98},[],{"intervention":471,"totalTrials":169,"cells":472},"Zimberelimab",{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":477,"PHASE3":490,"PHASE4":492,"NA":494},{"trials":474,"activeCount":98},[],{"trials":476,"activeCount":98},[],{"trials":478,"activeCount":169,"soonestReadout":483},[479],{"nctId":480,"briefTitle":481,"status":175,"phases":482,"primaryCompletion":483,"completion":484,"start":485,"enrollment":486,"conditions":487,"interventions":489},"NCT06009029","SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)",[88],"2026-07","2027-07","2023-08",96,[488],"Locally Advanced Pancreatic Cancer",[471],{"trials":491,"activeCount":98},[],{"trials":493,"activeCount":98},[],{"trials":495,"activeCount":98},[],{"intervention":497,"totalTrials":169,"cells":498},"Toripalimab",{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":516,"PHASE4":518,"NA":520},{"trials":500,"activeCount":98},[],{"trials":502,"activeCount":98},[],{"trials":504,"activeCount":169,"soonestReadout":509},[505],{"nctId":506,"briefTitle":507,"status":175,"phases":508,"primaryCompletion":509,"completion":509,"start":510,"enrollment":511,"conditions":512,"interventions":514},"NCT07412171","NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC",[88],"2028-12","2026-02",40,[513],"Upper Tract Urothelial Carcinoma",[497,515],"9MW2821",{"trials":517,"activeCount":98},[],{"trials":519,"activeCount":98},[],{"trials":521,"activeCount":98},[],{"intervention":515,"totalTrials":169,"cells":523},{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":534,"PHASE4":536,"NA":538},{"trials":525,"activeCount":98},[],{"trials":527,"activeCount":98},[],{"trials":529,"activeCount":169,"soonestReadout":509},[530],{"nctId":506,"briefTitle":507,"status":175,"phases":531,"primaryCompletion":509,"completion":509,"start":510,"enrollment":511,"conditions":532,"interventions":533},[88],[513],[497,515],{"trials":535,"activeCount":98},[],{"trials":537,"activeCount":98},[],{"trials":539,"activeCount":98},[],{"intervention":541,"totalTrials":169,"cells":542},"Treatment",{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":561,"PHASE4":563,"NA":565},{"trials":544,"activeCount":98},[],{"trials":546,"activeCount":98},[],{"trials":548,"activeCount":169,"soonestReadout":553},[549],{"nctId":550,"briefTitle":551,"status":175,"phases":552,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":557,"interventions":560},"NCT07339553","Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.",[88],"2029-01-30","2029-02-26","2026-01-04",30,[558,559],"Ovariancancer","Platinum-sensitive Recurrent",[541],{"trials":562,"activeCount":98},[],{"trials":564,"activeCount":98},[],{"trials":566,"activeCount":98},[],{"intervention":568,"totalTrials":169,"cells":569},"Nab paclitaxel",{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":574,"PHASE3":586,"PHASE4":588,"NA":590},{"trials":571,"activeCount":98},[],{"trials":573,"activeCount":98},[],{"trials":575,"activeCount":169,"soonestReadout":83},[576],{"nctId":577,"briefTitle":578,"status":175,"phases":579,"primaryCompletion":83,"completion":580,"start":581,"enrollment":288,"conditions":582,"interventions":584},"NCT06426056","Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.",[88],"2028-10","2024-06",[583],"Cervical Cancer",[568,585],"Cisplatin",{"trials":587,"activeCount":98},[],{"trials":589,"activeCount":98},[],{"trials":591,"activeCount":98},[],{"intervention":49,"totalTrials":169,"cells":593},{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":610,"PHASE4":612,"NA":614},{"trials":595,"activeCount":98},[],{"trials":597,"activeCount":98},[],{"trials":599,"activeCount":169,"soonestReadout":48},[600],{"nctId":46,"briefTitle":47,"status":110,"phases":601,"primaryCompletion":48,"completion":602,"start":603,"enrollment":604,"conditions":605,"interventions":609},[88],"2027-04-20","2021-04-19",75,[606,607,608],"Epithelial Ovarian Carcinoma","Fallopian Tube Carcinoma","Primary Peritoneal Carcinoma",[49],{"trials":611,"activeCount":98},[],{"trials":613,"activeCount":98},[],{"trials":615,"activeCount":98},[],{"intervention":617,"totalTrials":169,"cells":618},"Carilizumab and Apatinib",{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":634,"PHASE4":636,"NA":638},{"trials":620,"activeCount":98},[],{"trials":622,"activeCount":98},[],{"trials":624,"activeCount":169,"soonestReadout":240},[625],{"nctId":626,"briefTitle":627,"status":110,"phases":628,"primaryCompletion":240,"completion":629,"start":630,"enrollment":375,"conditions":631,"interventions":633},"NCT06792162","PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer",[88],"2027-04","2023-04-20",[632],"Gastric Cancer",[617],{"trials":635,"activeCount":98},[],{"trials":637,"activeCount":98},[],{"trials":639,"activeCount":98},[],{"intervention":641,"totalTrials":169,"cells":642},"anti-CD19 CAR-T cells",{"EARLY_PHASE1":643,"PHASE1":645,"PHASE2":647,"PHASE3":662,"PHASE4":664,"NA":666},{"trials":644,"activeCount":98},[],{"trials":646,"activeCount":98},[],{"trials":648,"activeCount":169,"soonestReadout":178},[649],{"nctId":650,"briefTitle":651,"status":175,"phases":652,"primaryCompletion":178,"completion":653,"start":179,"enrollment":654,"conditions":655,"interventions":661},"NCT06821659","Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases",[87,88],"2028-12-31",9,[656,657,658,659,660],"Systemic Lupus Erthematosus","Systemic Sclerosis (SSc)","Inflammatory Myopathies","ANCA Associated Vasculitis (AAV)","Sjogren Syndrome",[641],{"trials":663,"activeCount":98},[],{"trials":665,"activeCount":98},[],{"trials":667,"activeCount":98},[],{"intervention":669,"totalTrials":169,"cells":670},"anti-CD19 CAR T cell therapy",{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":685,"PHASE4":687,"NA":689},{"trials":672,"activeCount":98},[],{"trials":674,"activeCount":98},[],{"trials":676,"activeCount":169,"soonestReadout":178},[677],{"nctId":678,"briefTitle":679,"status":110,"phases":680,"primaryCompletion":178,"completion":178,"start":681,"enrollment":654,"conditions":682,"interventions":684},"NCT06828042","Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases",[87,88],"2025-07-01",[656,657,660,659,658,683],"Antiphospholipid Syndrome",[669],{"trials":686,"activeCount":98},[],{"trials":688,"activeCount":98},[],{"trials":690,"activeCount":98},[],{"intervention":585,"totalTrials":94,"cells":692},{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":703,"PHASE4":705,"NA":721},{"trials":694,"activeCount":98},[],{"trials":696,"activeCount":98},[],{"trials":698,"activeCount":169,"soonestReadout":83},[699],{"nctId":577,"briefTitle":578,"status":175,"phases":700,"primaryCompletion":83,"completion":580,"start":581,"enrollment":288,"conditions":701,"interventions":702},[88],[583],[568,585],{"trials":704,"activeCount":98},[],{"trials":706,"activeCount":98},[707],{"nctId":708,"briefTitle":709,"status":132,"phases":710,"primaryCompletion":711,"completion":134,"start":712,"enrollment":713,"conditions":714,"interventions":716},"NCT05730777","Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics",[90],"2023-07-01","2023-02-15",200,[715],"Cancer Therapy-related Cardiovascular Toxicity",[717,585,718,719,720],"Bifidobacterium Bifidum Oral","Carboplatin","Paclitaxel","Atlizumab",{"trials":722,"activeCount":98},[723],{"nctId":724,"briefTitle":725,"status":132,"phases":726,"primaryCompletion":727,"completion":728,"start":729,"enrollment":730,"conditions":731,"interventions":733},"NCT04678791","Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma",[91],"2024-12","2025-12","2020-12",286,[732],"Cervical Squamous Cell Carcinoma",[734,585],"Nimotuzumab",{"intervention":39,"totalTrials":169,"cells":736},{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":749,"PHASE3":751,"PHASE4":753,"NA":755},{"trials":738,"activeCount":98},[],{"trials":740,"activeCount":169,"soonestReadout":38},[741],{"nctId":36,"briefTitle":37,"status":175,"phases":742,"primaryCompletion":38,"completion":743,"start":744,"enrollment":745,"conditions":746,"interventions":748},[87],"2035-12-15","2021-03-15",12,[747],"B-cell Acute Lymphoblastic Leukemia",[39],{"trials":750,"activeCount":98},[],{"trials":752,"activeCount":98},[],{"trials":754,"activeCount":98},[],{"trials":756,"activeCount":98},[],{"intervention":758,"totalTrials":169,"cells":759},"BCT301",{"EARLY_PHASE1":760,"PHASE1":773,"PHASE2":775,"PHASE3":777,"PHASE4":779,"NA":781},{"trials":761,"activeCount":169,"soonestReadout":178},[762],{"nctId":763,"briefTitle":764,"status":175,"phases":765,"primaryCompletion":178,"completion":653,"start":766,"enrollment":767,"conditions":768,"interventions":772},"NCT07301164","Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases",[86],"2025-12-11",10,[769,657,770,683,771,660],"System Lupus Erythematosus","Inflammatory Myositis","ANCA Associated Vasculitis",[758],{"trials":774,"activeCount":98},[],{"trials":776,"activeCount":98},[],{"trials":778,"activeCount":98},[],{"trials":780,"activeCount":98},[],{"trials":782,"activeCount":98},[],{"intervention":69,"totalTrials":169,"cells":784},{"EARLY_PHASE1":785,"PHASE1":794,"PHASE2":796,"PHASE3":798,"PHASE4":800,"NA":802},{"trials":786,"activeCount":169,"soonestReadout":68},[787],{"nctId":66,"briefTitle":67,"status":175,"phases":788,"primaryCompletion":68,"completion":789,"start":790,"enrollment":31,"conditions":791,"interventions":793},[86],"2029-10-15","2024-10-16",[792],"Amyotrophic Lateral Sclerosis (ALS)",[69],{"trials":795,"activeCount":98},[],{"trials":797,"activeCount":98},[],{"trials":799,"activeCount":98},[],{"trials":801,"activeCount":98},[],{"trials":803,"activeCount":98},[],{"intervention":734,"totalTrials":94,"cells":805},{"EARLY_PHASE1":806,"PHASE1":808,"PHASE2":810,"PHASE3":822,"PHASE4":824,"NA":826},{"trials":807,"activeCount":98},[],{"trials":809,"activeCount":98},[],{"trials":811,"activeCount":98},[812],{"nctId":813,"briefTitle":814,"status":132,"phases":815,"primaryCompletion":816,"completion":816,"start":135,"enrollment":817,"conditions":818,"interventions":820},"NCT06422156","SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer",[88],"2026-06-01",73,[819],"Advanced Pancreatic Cancer",[734,821],"mono-chemotherapy",{"trials":823,"activeCount":98},[],{"trials":825,"activeCount":98},[],{"trials":827,"activeCount":169,"soonestReadout":728},[828,832],{"nctId":724,"briefTitle":725,"status":132,"phases":829,"primaryCompletion":727,"completion":728,"start":729,"enrollment":730,"conditions":830,"interventions":831},[91],[732],[734,585],{"nctId":833,"briefTitle":834,"status":175,"phases":835,"primaryCompletion":728,"completion":836,"start":837,"enrollment":838,"conditions":839,"interventions":840},"NCT04976478","Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma",[],"2026-12","2021-07",125,[732],[734],{"intervention":842,"totalTrials":126,"cells":843},"Letrozole",{"EARLY_PHASE1":844,"PHASE1":846,"PHASE2":848,"PHASE3":850,"PHASE4":852,"NA":854},{"trials":845,"activeCount":98},[],{"trials":847,"activeCount":98},[],{"trials":849,"activeCount":98},[],{"trials":851,"activeCount":98},[],{"trials":853,"activeCount":98},[],{"trials":855,"activeCount":169,"soonestReadout":728},[856,867],{"nctId":857,"briefTitle":858,"status":110,"phases":859,"primaryCompletion":728,"completion":860,"start":861,"enrollment":862,"conditions":863,"interventions":866},"NCT04169451","IUI With Letrozole Versus in Natural Cycle",[91],"2026-06","2022-09-29",982,[864,865],"Intrauterine Insemination","Unexplained Infertility",[842],{"nctId":868,"briefTitle":869,"status":870,"phases":871,"primaryCompletion":872,"completion":873,"start":874,"enrollment":115,"conditions":875,"interventions":876},"NCT03455426","Intrauterine Insemination With Letrozole Versus in Natural Cycle","COMPLETED",[91],"2019-06-30","2019-12-31","2018-03-15",[166,864],[877],"letrozole",{"intervention":879,"totalTrials":169,"cells":880},"Mailuo Shutong Pills",{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":885,"PHASE3":887,"PHASE4":889,"NA":891},{"trials":882,"activeCount":98},[],{"trials":884,"activeCount":98},[],{"trials":886,"activeCount":98},[],{"trials":888,"activeCount":98},[],{"trials":890,"activeCount":98},[],{"trials":892,"activeCount":169,"soonestReadout":897},[893],{"nctId":894,"briefTitle":895,"status":175,"phases":896,"primaryCompletion":897,"completion":898,"start":899,"enrollment":241,"conditions":900,"interventions":903},"NCT07258381","Mailuo Shutong Pills for Diabetic Wound Healing: A Multicenter Randomized Trial",[91],"2026-12-01","2027-12-01","2025-12-01",[901,902],"Diabetic Wound","Chronic Wound Care",[879,904],"Blank control",{"intervention":904,"totalTrials":169,"cells":906},{"EARLY_PHASE1":907,"PHASE1":909,"PHASE2":911,"PHASE3":913,"PHASE4":915,"NA":917},{"trials":908,"activeCount":98},[],{"trials":910,"activeCount":98},[],{"trials":912,"activeCount":98},[],{"trials":914,"activeCount":98},[],{"trials":916,"activeCount":98},[],{"trials":918,"activeCount":169,"soonestReadout":897},[919],{"nctId":894,"briefTitle":895,"status":175,"phases":920,"primaryCompletion":897,"completion":898,"start":899,"enrollment":241,"conditions":921,"interventions":922},[91],[901,902],[879,904],{"intervention":924,"totalTrials":169,"cells":925},"GAHT for transgender men",{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":932,"PHASE4":934,"NA":936},{"trials":927,"activeCount":98},[],{"trials":929,"activeCount":98},[],{"trials":931,"activeCount":98},[],{"trials":933,"activeCount":98},[],{"trials":935,"activeCount":98},[],{"trials":937,"activeCount":169,"soonestReadout":178},[938],{"nctId":939,"briefTitle":940,"status":110,"phases":941,"primaryCompletion":178,"completion":653,"start":942,"enrollment":943,"conditions":944,"interventions":947},"NCT05318755","China Gender-affirming Hormone Therapy Study",[],"2022-04-16",240,[945,946],"Transgender","Gender Incongruence",[924,948],"GAHT for transgender women",{"intervention":948,"totalTrials":169,"cells":950},{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":957,"PHASE4":959,"NA":961},{"trials":952,"activeCount":98},[],{"trials":954,"activeCount":98},[],{"trials":956,"activeCount":98},[],{"trials":958,"activeCount":98},[],{"trials":960,"activeCount":98},[],{"trials":962,"activeCount":169,"soonestReadout":178},[963],{"nctId":939,"briefTitle":940,"status":110,"phases":964,"primaryCompletion":178,"completion":653,"start":942,"enrollment":943,"conditions":965,"interventions":966},[],[945,946],[924,948],{"intervention":968,"totalTrials":169,"cells":969},"Infliximab",{"EARLY_PHASE1":970,"PHASE1":972,"PHASE2":974,"PHASE3":976,"PHASE4":978,"NA":980},{"trials":971,"activeCount":98},[],{"trials":973,"activeCount":98},[],{"trials":975,"activeCount":98},[],{"trials":977,"activeCount":98},[],{"trials":979,"activeCount":98},[],{"trials":981,"activeCount":169,"soonestReadout":986},[982],{"nctId":983,"briefTitle":984,"status":175,"phases":985,"primaryCompletion":986,"completion":987,"start":988,"enrollment":989,"conditions":990,"interventions":993},"NCT07176754","TNF-α Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest.",[91],"2028-07-31","2028-10-31","2025-10-01",208,[991,992],"Cardiac Arrest (CA)","Post Cardiac Arrest Syndrome",[968,994],"Sodium chloride injection USP, 0.9%",{"intervention":994,"totalTrials":169,"cells":996},{"EARLY_PHASE1":997,"PHASE1":999,"PHASE2":1001,"PHASE3":1003,"PHASE4":1005,"NA":1007},{"trials":998,"activeCount":98},[],{"trials":1000,"activeCount":98},[],{"trials":1002,"activeCount":98},[],{"trials":1004,"activeCount":98},[],{"trials":1006,"activeCount":98},[],{"trials":1008,"activeCount":169,"soonestReadout":986},[1009],{"nctId":983,"briefTitle":984,"status":175,"phases":1010,"primaryCompletion":986,"completion":987,"start":988,"enrollment":989,"conditions":1011,"interventions":1012},[91],[991,992],[968,994],{"intervention":1014,"totalTrials":169,"cells":1015},"total glucosides of paeony treatment",{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1020,"PHASE3":1022,"PHASE4":1024,"NA":1026},{"trials":1017,"activeCount":98},[],{"trials":1019,"activeCount":98},[],{"trials":1021,"activeCount":98},[],{"trials":1023,"activeCount":98},[],{"trials":1025,"activeCount":98},[],{"trials":1027,"activeCount":169,"soonestReadout":1032},[1028],{"nctId":1029,"briefTitle":1030,"status":110,"phases":1031,"primaryCompletion":1032,"completion":1032,"start":1033,"enrollment":1034,"conditions":1035,"interventions":1037},"NCT05973097","Treatment of Oral Lichen Planus With Paeoniflorin and Photodynamic Therapy",[91],"2028-12-30","2023-07-30",156,[1036],"Oral Lichen Planus",[1014],{"intervention":1039,"totalTrials":169,"cells":1040},"IM19 CAR-T cells",{"EARLY_PHASE1":1041,"PHASE1":1043,"PHASE2":1045,"PHASE3":1047,"PHASE4":1049,"NA":1051},{"trials":1042,"activeCount":98},[],{"trials":1044,"activeCount":98},[],{"trials":1046,"activeCount":98},[],{"trials":1048,"activeCount":98},[],{"trials":1050,"activeCount":98},[],{"trials":1052,"activeCount":169,"soonestReadout":112},[1053],{"nctId":1054,"briefTitle":1055,"status":110,"phases":1056,"primaryCompletion":112,"completion":178,"start":1057,"enrollment":1058,"conditions":1059,"interventions":1061},"NCT06513429","IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)",[91],"2024-07-30",6,[1060],"Refractory Systemic Lupus Erythematosus",[1039],{"intervention":185,"totalTrials":169,"cells":1063},{"EARLY_PHASE1":1064,"PHASE1":1066,"PHASE2":1068,"PHASE3":1070,"PHASE4":1072,"NA":1074},{"trials":1065,"activeCount":98},[],{"trials":1067,"activeCount":98},[],{"trials":1069,"activeCount":98},[],{"trials":1071,"activeCount":98},[],{"trials":1073,"activeCount":98},[],{"trials":1075,"activeCount":169,"soonestReadout":177},[1076],{"nctId":173,"briefTitle":174,"status":175,"phases":1077,"primaryCompletion":177,"completion":178,"start":179,"enrollment":180,"conditions":1078,"interventions":1079},[91],[182,165,183],[185,143],{"intervention":44,"totalTrials":169,"cells":1081},{"EARLY_PHASE1":1082,"PHASE1":1084,"PHASE2":1086,"PHASE3":1088,"PHASE4":1090,"NA":1092},{"trials":1083,"activeCount":98},[],{"trials":1085,"activeCount":98},[],{"trials":1087,"activeCount":98},[],{"trials":1089,"activeCount":98},[],{"trials":1091,"activeCount":98},[],{"trials":1093,"activeCount":169,"soonestReadout":43},[1094],{"nctId":41,"briefTitle":42,"status":175,"phases":1095,"primaryCompletion":43,"completion":1096,"start":1097,"enrollment":1098,"conditions":1099,"interventions":1101},[91],"2027-05-15","2022-06-15",180,[1100],"Stereotactic Body Radiation Therapy",[44],{"intervention":1103,"totalTrials":169,"cells":1104},"Eravacycline combination therapy group",{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1106,"activeCount":98},[],{"trials":1108,"activeCount":98},[],{"trials":1110,"activeCount":98},[],{"trials":1112,"activeCount":98},[],{"trials":1114,"activeCount":98},[],{"trials":1116,"activeCount":169,"soonestReadout":1121},[1117],{"nctId":1118,"briefTitle":1119,"status":175,"phases":1120,"primaryCompletion":1121,"completion":1122,"start":1123,"enrollment":1124,"conditions":1125,"interventions":1128},"NCT06670872","A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia",[],"2025-10","2026-10","2024-10",50,[1126,1127],"Pneumonitis","Acinetobacter Baumannii",[1103],{"intervention":1130,"totalTrials":169,"cells":1131},"Weight loss and psoriasis treatment",{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1138,"PHASE4":1140,"NA":1142},{"trials":1133,"activeCount":98},[],{"trials":1135,"activeCount":98},[],{"trials":1137,"activeCount":98},[],{"trials":1139,"activeCount":98},[],{"trials":1141,"activeCount":98},[],{"trials":1143,"activeCount":169,"soonestReadout":178},[1144],{"nctId":1145,"briefTitle":1146,"status":175,"phases":1147,"primaryCompletion":178,"completion":178,"start":1148,"enrollment":1149,"conditions":1150,"interventions":1152},"NCT07382388","A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight\u002FObese Patients With Plaque Psoriasis",[],"2026-01-28",70,[1151],"Psoriasis",[1130,1153],"psoriasis treatment",{"intervention":1153,"totalTrials":169,"cells":1155},{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1160,"PHASE3":1162,"PHASE4":1164,"NA":1166},{"trials":1157,"activeCount":98},[],{"trials":1159,"activeCount":98},[],{"trials":1161,"activeCount":98},[],{"trials":1163,"activeCount":98},[],{"trials":1165,"activeCount":98},[],{"trials":1167,"activeCount":169,"soonestReadout":178},[1168],{"nctId":1145,"briefTitle":1146,"status":175,"phases":1169,"primaryCompletion":178,"completion":178,"start":1148,"enrollment":1149,"conditions":1170,"interventions":1171},[],[1151],[1130,1153],{"intervention":84,"totalTrials":169,"cells":1173},{"EARLY_PHASE1":1174,"PHASE1":1176,"PHASE2":1178,"PHASE3":1180,"PHASE4":1182,"NA":1184},{"trials":1175,"activeCount":98},[],{"trials":1177,"activeCount":98},[],{"trials":1179,"activeCount":98},[],{"trials":1181,"activeCount":98},[],{"trials":1183,"activeCount":98},[],{"trials":1185,"activeCount":169,"soonestReadout":83},[1186],{"nctId":81,"briefTitle":82,"status":1187,"phases":1188,"primaryCompletion":83,"completion":1189,"start":1190,"enrollment":1191,"conditions":1192,"interventions":1195},"ENROLLING_BY_INVITATION",[],"2029-08","2024-10-15",167,[1193,1194],"Non-Small Cell Lung Cancer","Hyperlipidemia",[84],{"intervention":1197,"totalTrials":169,"cells":1198},"Budesonide irrigation",{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1203,"PHASE3":1205,"PHASE4":1207,"NA":1209},{"trials":1200,"activeCount":98},[],{"trials":1202,"activeCount":98},[],{"trials":1204,"activeCount":98},[],{"trials":1206,"activeCount":98},[],{"trials":1208,"activeCount":98},[],{"trials":1210,"activeCount":169,"soonestReadout":1215},[1211],{"nctId":1212,"briefTitle":1213,"status":175,"phases":1214,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":1217,"conditions":1218,"interventions":1221},"NCT06837051","The Effect of Modified Olfactory Training on Postoperative Olfactory Dysfunction in Patients With CRS",[91],"2027-03-14","2025-03-14",213,[1219,1220],"Olfactory Dysfunction","Chronic Rhinosinusitis",[1197],{"intervention":1223,"totalTrials":169,"cells":1224},"Pomalidomide",{"EARLY_PHASE1":1225,"PHASE1":1227,"PHASE2":1229,"PHASE3":1231,"PHASE4":1233,"NA":1235},{"trials":1226,"activeCount":98},[],{"trials":1228,"activeCount":98},[],{"trials":1230,"activeCount":98},[],{"trials":1232,"activeCount":98},[],{"trials":1234,"activeCount":98},[],{"trials":1236,"activeCount":169,"soonestReadout":1241},[1237],{"nctId":1238,"briefTitle":1239,"status":110,"phases":1240,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":1243,"conditions":1244,"interventions":1247},"NCT07257510","Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma",[91],"2028-08-01","2025-08-01",34,[1245,1246],"Mantle Cell Lymphoma (MCL)","POZ",[1223,1248,1249,1249],"Orelabrutinib","Zuberitamab",{"intervention":1248,"totalTrials":169,"cells":1251},{"EARLY_PHASE1":1252,"PHASE1":1254,"PHASE2":1256,"PHASE3":1258,"PHASE4":1260,"NA":1262},{"trials":1253,"activeCount":98},[],{"trials":1255,"activeCount":98},[],{"trials":1257,"activeCount":98},[],{"trials":1259,"activeCount":98},[],{"trials":1261,"activeCount":98},[],{"trials":1263,"activeCount":169,"soonestReadout":1241},[1264],{"nctId":1238,"briefTitle":1239,"status":110,"phases":1265,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":1243,"conditions":1266,"interventions":1267},[91],[1245,1246],[1223,1248,1249,1249],{"intervention":1249,"totalTrials":169,"cells":1269},{"EARLY_PHASE1":1270,"PHASE1":1272,"PHASE2":1274,"PHASE3":1276,"PHASE4":1278,"NA":1280},{"trials":1271,"activeCount":98},[],{"trials":1273,"activeCount":98},[],{"trials":1275,"activeCount":98},[],{"trials":1277,"activeCount":98},[],{"trials":1279,"activeCount":98},[],{"trials":1281,"activeCount":169,"soonestReadout":1241},[1282],{"nctId":1238,"briefTitle":1239,"status":110,"phases":1283,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":1243,"conditions":1284,"interventions":1285},[91],[1245,1246],[1223,1248,1249,1249],{"intervention":1287,"totalTrials":169,"cells":1288},"Traditional Chinese Medicine",{"EARLY_PHASE1":1289,"PHASE1":1291,"PHASE2":1293,"PHASE3":1295,"PHASE4":1297,"NA":1299},{"trials":1290,"activeCount":98},[],{"trials":1292,"activeCount":98},[],{"trials":1294,"activeCount":98},[],{"trials":1296,"activeCount":98},[],{"trials":1298,"activeCount":98},[],{"trials":1300,"activeCount":169,"soonestReadout":1305},[1301],{"nctId":1302,"briefTitle":1303,"status":175,"phases":1304,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":1307,"conditions":1308,"interventions":1310},"NCT07375446","Traditional Chinese Medicine Hand-Foot Soak for Chemotherapy-Induced Peripheral Neuropathy and Hand-Foot Syndrome",[],"2029-01-31","2026-02-01",300,[1309],"Patients With Solid Tumors",[1287],{"intervention":1312,"totalTrials":169,"cells":1313},"Ruxolitinib 1.5% Cream BID",{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1318,"PHASE3":1320,"PHASE4":1322,"NA":1324},{"trials":1315,"activeCount":98},[],{"trials":1317,"activeCount":98},[],{"trials":1319,"activeCount":98},[],{"trials":1321,"activeCount":98},[],{"trials":1323,"activeCount":98},[],{"trials":1325,"activeCount":169,"soonestReadout":1330},[1326],{"nctId":1327,"briefTitle":1328,"status":110,"phases":1329,"primaryCompletion":1330,"completion":178,"start":1331,"enrollment":1332,"conditions":1333,"interventions":1335},"NCT07153666","A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo",[],"2027-06-30","2025-12-08",170,[1334],"Vitiligo",[1312],{"intervention":59,"totalTrials":169,"cells":1337},{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1344,"PHASE4":1346,"NA":1348},{"trials":1339,"activeCount":98},[],{"trials":1341,"activeCount":98},[],{"trials":1343,"activeCount":98},[],{"trials":1345,"activeCount":98},[],{"trials":1347,"activeCount":98},[],{"trials":1349,"activeCount":169,"soonestReadout":58},[1350],{"nctId":56,"briefTitle":57,"status":175,"phases":1351,"primaryCompletion":58,"completion":1352,"start":1353,"enrollment":16,"conditions":1354,"interventions":1355},[],"2027-10-11","2023-10-11",[583],[59],{"intervention":1357,"totalTrials":169,"cells":1358},"Suspective gene mutations and family history",{"EARLY_PHASE1":1359,"PHASE1":1361,"PHASE2":1363,"PHASE3":1365,"PHASE4":1367,"NA":1369},{"trials":1360,"activeCount":98},[],{"trials":1362,"activeCount":98},[],{"trials":1364,"activeCount":98},[],{"trials":1366,"activeCount":98},[],{"trials":1368,"activeCount":98},[],{"trials":1370,"activeCount":169,"soonestReadout":177},[1371],{"nctId":1372,"briefTitle":1373,"status":110,"phases":1374,"primaryCompletion":177,"completion":177,"start":1375,"enrollment":1376,"conditions":1377,"interventions":1379},"NCT06564428","A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration",[],"2024-01-01",1000,[1378],"Ovarian Neoplasms",[1357],{"intervention":1381,"totalTrials":169,"cells":1382},"Autologous NK cells",{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1387,"PHASE3":1389,"PHASE4":1391,"NA":1393},{"trials":1384,"activeCount":98},[],{"trials":1386,"activeCount":98},[],{"trials":1388,"activeCount":98},[],{"trials":1390,"activeCount":98},[],{"trials":1392,"activeCount":98},[],{"trials":1394,"activeCount":169,"soonestReadout":1399},[1395],{"nctId":1396,"briefTitle":1397,"status":110,"phases":1398,"primaryCompletion":1399,"completion":1400,"start":240,"enrollment":1401,"conditions":1402,"interventions":1408},"NCT07552233","NK Cell Therapy for Malignant Solid Brain Tumors",[91],"2030-12","2030-12-31",27,[1403,1404,1405,1406,1407],"Malignant Solid Brain Tumors","Glioblastoma (GBM)","Glioblastoma Multiforme (GBM)","Brain Metastasis","Malignant Meningioma",[1381],{"intervention":1410,"totalTrials":169,"cells":1411},"Exercise，Nutrition，Bisphosphonates，Statins，Calcitonin,Vitamin D，et al.",{"EARLY_PHASE1":1412,"PHASE1":1414,"PHASE2":1416,"PHASE3":1418,"PHASE4":1420,"NA":1422},{"trials":1413,"activeCount":98},[],{"trials":1415,"activeCount":98},[],{"trials":1417,"activeCount":98},[],{"trials":1419,"activeCount":98},[],{"trials":1421,"activeCount":98},[],{"trials":1423,"activeCount":169,"soonestReadout":1429},[1424],{"nctId":1425,"briefTitle":1426,"status":1427,"phases":1428,"primaryCompletion":1429,"completion":1430,"start":1431,"enrollment":1432,"conditions":1433,"interventions":1435},"NCT03401619","Beijing Osteoporosis With Neurological Disorders in Epigenetic Changes Study","ACTIVE_NOT_RECRUITING",[],"2026-09-22","2027-09-22","2017-09-21",2000,[1434],"Osteoporosis，Neurological Disorders",[1410],{"intervention":1437,"totalTrials":169,"cells":1438},"Darolutamide in addition to androgen deprivation therapy",{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1445,"PHASE4":1447,"NA":1449},{"trials":1440,"activeCount":98},[],{"trials":1442,"activeCount":98},[],{"trials":1444,"activeCount":98},[],{"trials":1446,"activeCount":98},[],{"trials":1448,"activeCount":98},[],{"trials":1450,"activeCount":169,"soonestReadout":1455},[1451],{"nctId":1452,"briefTitle":1453,"status":175,"phases":1454,"primaryCompletion":1455,"completion":160,"start":135,"enrollment":1456,"conditions":1457,"interventions":1459},"NCT06435702","Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study",[],"2026-07-01",108,[1458],"Prostate Cancer",[1437,1460],"androgen deprivation therapy only",{"intervention":1460,"totalTrials":169,"cells":1462},{"EARLY_PHASE1":1463,"PHASE1":1465,"PHASE2":1467,"PHASE3":1469,"PHASE4":1471,"NA":1473},{"trials":1464,"activeCount":98},[],{"trials":1466,"activeCount":98},[],{"trials":1468,"activeCount":98},[],{"trials":1470,"activeCount":98},[],{"trials":1472,"activeCount":98},[],{"trials":1474,"activeCount":169,"soonestReadout":1455},[1475],{"nctId":1452,"briefTitle":1453,"status":175,"phases":1476,"primaryCompletion":1455,"completion":160,"start":135,"enrollment":1456,"conditions":1477,"interventions":1478},[],[1458],[1437,1460],{"intervention":1480,"totalTrials":169,"cells":1481},"Fuzheng Yangxin prescription",{"EARLY_PHASE1":1482,"PHASE1":1484,"PHASE2":1486,"PHASE3":1488,"PHASE4":1490,"NA":1492},{"trials":1483,"activeCount":98},[],{"trials":1485,"activeCount":98},[],{"trials":1487,"activeCount":98},[],{"trials":1489,"activeCount":98},[],{"trials":1491,"activeCount":98},[],{"trials":1493,"activeCount":169,"soonestReadout":816},[1494],{"nctId":1495,"briefTitle":1496,"status":110,"phases":1497,"primaryCompletion":816,"completion":1498,"start":1499,"enrollment":1307,"conditions":1500,"interventions":1502},"NCT06961136","Prospective Cohort Study on Fuzheng Yangxin Prescription For Rapid Rehabilitation of Patients With Qi-Yin Deficiency Syndrome After Coronary Artery Bypass Grafting",[],"2026-06-30","2025-05-10",[1501],"Coronary Artery Bypass",[1480],{"intervention":1504,"totalTrials":169,"cells":1505},"No Interventions",{"EARLY_PHASE1":1506,"PHASE1":1508,"PHASE2":1510,"PHASE3":1512,"PHASE4":1514,"NA":1516},{"trials":1507,"activeCount":98},[],{"trials":1509,"activeCount":98},[],{"trials":1511,"activeCount":98},[],{"trials":1513,"activeCount":98},[],{"trials":1515,"activeCount":98},[],{"trials":1517,"activeCount":169,"soonestReadout":112},[1518],{"nctId":1519,"briefTitle":1520,"status":1187,"phases":1521,"primaryCompletion":112,"completion":1455,"start":1522,"enrollment":1523,"conditions":1524,"interventions":1527},"NCT06645223","Correlation Between Gut Microbiota and Pancreatic Β-Cell Function in Diabetic Patients",[],"2024-09-20",160,[1525,1526],"Diabetes Mellitus","Gut Microbiota",[1504],{"intervention":1529,"totalTrials":169,"cells":1530},"Sitagliptin",{"EARLY_PHASE1":1531,"PHASE1":1533,"PHASE2":1535,"PHASE3":1537,"PHASE4":1539,"NA":1541},{"trials":1532,"activeCount":98},[],{"trials":1534,"activeCount":98},[],{"trials":1536,"activeCount":98},[],{"trials":1538,"activeCount":98},[],{"trials":1540,"activeCount":98},[],{"trials":1542,"activeCount":169,"soonestReadout":1547},[1543],{"nctId":1544,"briefTitle":1545,"status":110,"phases":1546,"primaryCompletion":1547,"completion":1548,"start":1549,"enrollment":1307,"conditions":1550,"interventions":1552},"NCT06587698","Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS",[91],"2028-07-01","2029-07-01","2024-08-21",[1551],"Polycystic Ovarian Syndrome",[1529,1553,1554],"BeiDouGen","Sitagliptin+BeiDouGen",{"intervention":1553,"totalTrials":169,"cells":1556},{"EARLY_PHASE1":1557,"PHASE1":1559,"PHASE2":1561,"PHASE3":1563,"PHASE4":1565,"NA":1567},{"trials":1558,"activeCount":98},[],{"trials":1560,"activeCount":98},[],{"trials":1562,"activeCount":98},[],{"trials":1564,"activeCount":98},[],{"trials":1566,"activeCount":98},[],{"trials":1568,"activeCount":169,"soonestReadout":1547},[1569],{"nctId":1544,"briefTitle":1545,"status":110,"phases":1570,"primaryCompletion":1547,"completion":1548,"start":1549,"enrollment":1307,"conditions":1571,"interventions":1572},[91],[1551],[1529,1553,1554],{"intervention":1554,"totalTrials":169,"cells":1574},{"EARLY_PHASE1":1575,"PHASE1":1577,"PHASE2":1579,"PHASE3":1581,"PHASE4":1583,"NA":1585},{"trials":1576,"activeCount":98},[],{"trials":1578,"activeCount":98},[],{"trials":1580,"activeCount":98},[],{"trials":1582,"activeCount":98},[],{"trials":1584,"activeCount":98},[],{"trials":1586,"activeCount":169,"soonestReadout":1547},[1587],{"nctId":1544,"briefTitle":1545,"status":110,"phases":1588,"primaryCompletion":1547,"completion":1548,"start":1549,"enrollment":1307,"conditions":1589,"interventions":1590},[91],[1551],[1529,1553,1554],{"intervention":1592,"totalTrials":169,"cells":1593},"Medication",{"EARLY_PHASE1":1594,"PHASE1":1596,"PHASE2":1598,"PHASE3":1600,"PHASE4":1602,"NA":1604},{"trials":1595,"activeCount":98},[],{"trials":1597,"activeCount":98},[],{"trials":1599,"activeCount":98},[],{"trials":1601,"activeCount":98},[],{"trials":1603,"activeCount":98},[],{"trials":1605,"activeCount":169,"soonestReadout":653},[1606],{"nctId":1607,"briefTitle":1608,"status":175,"phases":1609,"primaryCompletion":653,"completion":653,"start":1610,"enrollment":1611,"conditions":1612,"interventions":1624},"NCT06967363","Multimodal Imaging and Biospecimen Collection for Low Back Pain (LBPB)",[],"2025-05-15",360,[1613,1614,1615,1616,1617,1618,1619,1620,1621,1622,1623],"Chronic Low Back Pain (CLBP)","Acute Low Back Pain","Low Back Pain","Chronic Pain","Acute Pain","Mental Disorders","Sleep Disorder","Fibromyalgia (FM)","Nociplastic Pain","Neuropathic Pain","Nonspecific Low Back Pain",[1592],{"intervention":1626,"totalTrials":169,"cells":1627},"Modified olfactory training device",{"EARLY_PHASE1":1628,"PHASE1":1630,"PHASE2":1632,"PHASE3":1634,"PHASE4":1636,"NA":1638},{"trials":1629,"activeCount":98},[],{"trials":1631,"activeCount":98},[],{"trials":1633,"activeCount":98},[],{"trials":1635,"activeCount":98},[],{"trials":1637,"activeCount":98},[],{"trials":1639,"activeCount":169,"soonestReadout":1644},[1640],{"nctId":1641,"briefTitle":1642,"status":175,"phases":1643,"primaryCompletion":1644,"completion":1645,"start":1646,"enrollment":1647,"conditions":1648,"interventions":1652},"NCT06821828","The Efficacy of Modified Olfactory Training for MCI High-Risk Individuals",[91],"2027-03-22","2027-05-22","2025-03-22",114,[1649,1219,1650,1651],"Subjective Cognitive Decline (SCD)","Mild Cognitive Impairment (MCI)","ELDERLY PEOPLE",[1626,1653],"Conventional olfactory training device",{"intervention":1653,"totalTrials":169,"cells":1655},{"EARLY_PHASE1":1656,"PHASE1":1658,"PHASE2":1660,"PHASE3":1662,"PHASE4":1664,"NA":1666},{"trials":1657,"activeCount":98},[],{"trials":1659,"activeCount":98},[],{"trials":1661,"activeCount":98},[],{"trials":1663,"activeCount":98},[],{"trials":1665,"activeCount":98},[],{"trials":1667,"activeCount":169,"soonestReadout":1644},[1668],{"nctId":1641,"briefTitle":1642,"status":175,"phases":1669,"primaryCompletion":1644,"completion":1645,"start":1646,"enrollment":1647,"conditions":1670,"interventions":1671},[91],[1649,1219,1650,1651],[1626,1653],{"intervention":74,"totalTrials":169,"cells":1673},{"EARLY_PHASE1":1674,"PHASE1":1676,"PHASE2":1678,"PHASE3":1680,"PHASE4":1682,"NA":1684},{"trials":1675,"activeCount":98},[],{"trials":1677,"activeCount":98},[],{"trials":1679,"activeCount":98},[],{"trials":1681,"activeCount":98},[],{"trials":1683,"activeCount":98},[],{"trials":1685,"activeCount":169,"soonestReadout":73},[1686],{"nctId":71,"briefTitle":72,"status":175,"phases":1687,"primaryCompletion":73,"completion":1688,"start":1689,"enrollment":713,"conditions":1690,"interventions":1691},[],"2026-07-31","2024-08-01",[632],[74],{"intervention":1693,"totalTrials":169,"cells":1694},"Steroid nasal drops combined with olfactory training",{"EARLY_PHASE1":1695,"PHASE1":1697,"PHASE2":1699,"PHASE3":1701,"PHASE4":1703,"NA":1705},{"trials":1696,"activeCount":98},[],{"trials":1698,"activeCount":98},[],{"trials":1700,"activeCount":98},[],{"trials":1702,"activeCount":98},[],{"trials":1704,"activeCount":98},[],{"trials":1706,"activeCount":169,"soonestReadout":653},[1707],{"nctId":1708,"briefTitle":1709,"status":175,"phases":1710,"primaryCompletion":653,"completion":653,"start":1711,"enrollment":115,"conditions":1712,"interventions":1714},"NCT07386860","The Effectiveness of Steroid Nasal Drops in the Olfactory Cleft Combined With Olfactory Training for Patients With PIOD",[91],"2026-03-01",[1713],"Smell Dysfunction",[1693],{"intervention":1716,"totalTrials":169,"cells":1717},"Voltaren",{"EARLY_PHASE1":1718,"PHASE1":1720,"PHASE2":1722,"PHASE3":1724,"PHASE4":1726,"NA":1728},{"trials":1719,"activeCount":98},[],{"trials":1721,"activeCount":98},[],{"trials":1723,"activeCount":98},[],{"trials":1725,"activeCount":98},[],{"trials":1727,"activeCount":98},[],{"trials":1729,"activeCount":169,"soonestReadout":1498},[1730],{"nctId":1731,"briefTitle":1732,"status":1427,"phases":1733,"primaryCompletion":1498,"completion":1498,"start":135,"enrollment":1734,"conditions":1735,"interventions":1737},"NCT07613346","Integrated Traditional Chinese and Western Medicine for Patellar Dislocation Pain: A Concurrent Non-Randomized Controlled Trial",[91],80,[1736],"Postoperative Pain After Patellar Dislocation Surgery",[1716],{"intervention":1739,"totalTrials":169,"cells":1740},"Tumor Neoantigen-Sensitized Autologous Dendritic Cell",{"EARLY_PHASE1":1741,"PHASE1":1743,"PHASE2":1745,"PHASE3":1747,"PHASE4":1749,"NA":1751},{"trials":1742,"activeCount":98},[],{"trials":1744,"activeCount":98},[],{"trials":1746,"activeCount":98},[],{"trials":1748,"activeCount":98},[],{"trials":1750,"activeCount":98},[],{"trials":1752,"activeCount":169,"soonestReadout":286},[1753],{"nctId":1754,"briefTitle":1755,"status":175,"phases":1756,"primaryCompletion":286,"completion":1757,"start":1711,"enrollment":654,"conditions":1758,"interventions":1760},"NCT07455071","A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer",[91],"2027-11-30",[1759],"HRD-negative Epithelial Ovarian Cancer",[1739],{"intervention":1762,"totalTrials":169,"cells":1763},"Levofloxacin Plus Metronidazole Suppositories",{"EARLY_PHASE1":1764,"PHASE1":1766,"PHASE2":1768,"PHASE3":1770,"PHASE4":1772,"NA":1774},{"trials":1765,"activeCount":98},[],{"trials":1767,"activeCount":98},[],{"trials":1769,"activeCount":98},[],{"trials":1771,"activeCount":98},[],{"trials":1773,"activeCount":98},[],{"trials":1775,"activeCount":169,"soonestReadout":1780},[1776],{"nctId":1777,"briefTitle":1778,"status":175,"phases":1779,"primaryCompletion":1780,"completion":1781,"start":1782,"enrollment":1783,"conditions":1784,"interventions":1786},"NCT06650540","Levofloxacin Plus Metronidazole Suppositories Versus Levofloxacin Co-administered with Metronidazole Tablets in Chronic Endometritis",[91],"2025-10-22","2026-12-30","2024-10-22",800,[1785],"IVF",[1762,1787],"Levofloxacin co-administered with Metronidazole",{"intervention":1787,"totalTrials":169,"cells":1789},{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1794,"PHASE3":1796,"PHASE4":1798,"NA":1800},{"trials":1791,"activeCount":98},[],{"trials":1793,"activeCount":98},[],{"trials":1795,"activeCount":98},[],{"trials":1797,"activeCount":98},[],{"trials":1799,"activeCount":98},[],{"trials":1801,"activeCount":169,"soonestReadout":1780},[1802],{"nctId":1777,"briefTitle":1778,"status":175,"phases":1803,"primaryCompletion":1780,"completion":1781,"start":1782,"enrollment":1783,"conditions":1804,"interventions":1805},[91],[1785],[1762,1787],{"intervention":1807,"totalTrials":169,"cells":1808},"Allogeneic γδ T (ABOUT) cells",{"EARLY_PHASE1":1809,"PHASE1":1811,"PHASE2":1813,"PHASE3":1815,"PHASE4":1817,"NA":1819},{"trials":1810,"activeCount":98},[],{"trials":1812,"activeCount":98},[],{"trials":1814,"activeCount":98},[],{"trials":1816,"activeCount":98},[],{"trials":1818,"activeCount":98},[],{"trials":1820,"activeCount":169,"soonestReadout":238},[1821],{"nctId":1822,"briefTitle":1823,"status":110,"phases":1824,"primaryCompletion":238,"completion":1399,"start":1825,"enrollment":16,"conditions":1826,"interventions":1827},"NCT07144735","Allogeneic γδT Cells in Glioblastoma",[91],"2025-04-01",[1404,1405],[1807],{"intervention":1829,"totalTrials":169,"cells":1830},"Conservative management of ankylosing spondylitis",{"EARLY_PHASE1":1831,"PHASE1":1833,"PHASE2":1835,"PHASE3":1837,"PHASE4":1839,"NA":1841},{"trials":1832,"activeCount":98},[],{"trials":1834,"activeCount":98},[],{"trials":1836,"activeCount":98},[],{"trials":1838,"activeCount":98},[],{"trials":1840,"activeCount":98},[],{"trials":1842,"activeCount":169,"soonestReadout":1847},[1843],{"nctId":1844,"briefTitle":1845,"status":1427,"phases":1846,"primaryCompletion":1847,"completion":1400,"start":1848,"enrollment":1849,"conditions":1850,"interventions":1853},"NCT07093827","A Prospective Cohort Study on the Effect of Spinal Spinal Cord Injury on Sexual Function in Male Patients",[],"2030-01-31","2020-01-01",1600,[1851,1852],"Sexual Function Abnormal","Spinal Cord Injuries (SCI)",[1829,1854],"Conservative management of lumbar spinal stenosis",{"intervention":1854,"totalTrials":169,"cells":1856},{"EARLY_PHASE1":1857,"PHASE1":1859,"PHASE2":1861,"PHASE3":1863,"PHASE4":1865,"NA":1867},{"trials":1858,"activeCount":98},[],{"trials":1860,"activeCount":98},[],{"trials":1862,"activeCount":98},[],{"trials":1864,"activeCount":98},[],{"trials":1866,"activeCount":98},[],{"trials":1868,"activeCount":169,"soonestReadout":1847},[1869],{"nctId":1844,"briefTitle":1845,"status":1427,"phases":1870,"primaryCompletion":1847,"completion":1400,"start":1848,"enrollment":1849,"conditions":1871,"interventions":1872},[],[1851,1852],[1829,1854],{"intervention":1874,"totalTrials":169,"cells":1875},"Conservative treatment",{"EARLY_PHASE1":1876,"PHASE1":1878,"PHASE2":1880,"PHASE3":1882,"PHASE4":1884,"NA":1886},{"trials":1877,"activeCount":98},[],{"trials":1879,"activeCount":98},[],{"trials":1881,"activeCount":98},[],{"trials":1883,"activeCount":98},[],{"trials":1885,"activeCount":98},[],{"trials":1887,"activeCount":169,"soonestReadout":177},[1888],{"nctId":1889,"briefTitle":1890,"status":110,"phases":1891,"primaryCompletion":177,"completion":177,"start":1375,"enrollment":1892,"conditions":1893,"interventions":1896},"NCT06953622","Establishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale",[],330,[1894,1895],"Migraine","Patent Foramen Ovale",[1874,1897],"Antipaletet drug",{"intervention":1897,"totalTrials":169,"cells":1899},{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1904,"PHASE3":1906,"PHASE4":1908,"NA":1910},{"trials":1901,"activeCount":98},[],{"trials":1903,"activeCount":98},[],{"trials":1905,"activeCount":98},[],{"trials":1907,"activeCount":98},[],{"trials":1909,"activeCount":98},[],{"trials":1911,"activeCount":169,"soonestReadout":177},[1912],{"nctId":1889,"briefTitle":1890,"status":110,"phases":1913,"primaryCompletion":177,"completion":177,"start":1375,"enrollment":1892,"conditions":1914,"interventions":1915},[],[1894,1895],[1874,1897],{"intervention":1917,"totalTrials":126,"cells":1918},"artificial tear eyedrops",{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1923,"PHASE3":1925,"PHASE4":1927,"NA":1947},{"trials":1920,"activeCount":98},[],{"trials":1922,"activeCount":98},[],{"trials":1924,"activeCount":98},[],{"trials":1926,"activeCount":98},[],{"trials":1928,"activeCount":98},[1929,1938],{"nctId":1930,"briefTitle":1931,"status":132,"phases":1932,"primaryCompletion":134,"completion":134,"start":1933,"enrollment":1934,"conditions":1935,"interventions":1936},"NCT06043908","The Effect of 0.05% CsA Eye Drops on Post-refractive Surgery Dry Eye",[90],"2022-08-31",60,[25],[1917,1937],"0.05% cyclosporine eyedrops",{"nctId":1939,"briefTitle":1940,"status":870,"phases":1941,"primaryCompletion":1942,"completion":1943,"start":1944,"enrollment":1934,"conditions":1945,"interventions":1946},"NCT06824844","The Effect of 0.05% CsA Eye Drops on Diabetic Patients with Dry Eye Disease",[90],"2024-03-04","2024-06-04","2021-12-02",[25],[1917,1937],{"trials":1948,"activeCount":98},[],{"intervention":1937,"totalTrials":126,"cells":1950},{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1955,"PHASE3":1957,"PHASE4":1959,"NA":1969},{"trials":1952,"activeCount":98},[],{"trials":1954,"activeCount":98},[],{"trials":1956,"activeCount":98},[],{"trials":1958,"activeCount":98},[],{"trials":1960,"activeCount":98},[1961,1965],{"nctId":1930,"briefTitle":1931,"status":132,"phases":1962,"primaryCompletion":134,"completion":134,"start":1933,"enrollment":1934,"conditions":1963,"interventions":1964},[90],[25],[1917,1937],{"nctId":1939,"briefTitle":1940,"status":870,"phases":1966,"primaryCompletion":1942,"completion":1943,"start":1944,"enrollment":1934,"conditions":1967,"interventions":1968},[90],[25],[1917,1937],{"trials":1970,"activeCount":98},[],{"intervention":1972,"totalTrials":169,"cells":1973},"Cyclosporine",{"EARLY_PHASE1":1974,"PHASE1":1976,"PHASE2":1978,"PHASE3":1980,"PHASE4":1982,"NA":1996},{"trials":1975,"activeCount":98},[],{"trials":1977,"activeCount":98},[],{"trials":1979,"activeCount":98},[],{"trials":1981,"activeCount":98},[],{"trials":1983,"activeCount":98},[1984],{"nctId":1985,"briefTitle":1986,"status":870,"phases":1987,"primaryCompletion":1988,"completion":1989,"start":1990,"enrollment":1991,"conditions":1992,"interventions":1994},"NCT05294666","Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment",[90],"2021-06-01","2021-07-01","2020-04-01",89,[1993],"Graft Versus Host Disease in Eye",[1972,1995],"tacrolimus",{"trials":1997,"activeCount":98},[],{"intervention":1995,"totalTrials":169,"cells":1999},{"EARLY_PHASE1":2000,"PHASE1":2002,"PHASE2":2004,"PHASE3":2006,"PHASE4":2008,"NA":2014},{"trials":2001,"activeCount":98},[],{"trials":2003,"activeCount":98},[],{"trials":2005,"activeCount":98},[],{"trials":2007,"activeCount":98},[],{"trials":2009,"activeCount":98},[2010],{"nctId":1985,"briefTitle":1986,"status":870,"phases":2011,"primaryCompletion":1988,"completion":1989,"start":1990,"enrollment":1991,"conditions":2012,"interventions":2013},[90],[1993],[1972,1995],{"trials":2015,"activeCount":98},[],{"intervention":2017,"totalTrials":169,"cells":2018},"Shuxinin",{"EARLY_PHASE1":2019,"PHASE1":2021,"PHASE2":2023,"PHASE3":2025,"PHASE4":2027,"NA":2040},{"trials":2020,"activeCount":98},[],{"trials":2022,"activeCount":98},[],{"trials":2024,"activeCount":98},[],{"trials":2026,"activeCount":98},[],{"trials":2028,"activeCount":98},[2029],{"nctId":2030,"briefTitle":2031,"status":132,"phases":2032,"primaryCompletion":2033,"completion":2033,"start":2034,"enrollment":2035,"conditions":2036,"interventions":2038},"NCT04950790","Study on the Effectiveness and Safety of Shuxinin Injection in the Treatment of Acute Ischemic Stroke",[90],"2021-12-01","2018-04-01",480,[2037],"Acute Ischemic Stroke",[2017,2039],"Basic treatment",{"trials":2041,"activeCount":98},[],{"intervention":2039,"totalTrials":169,"cells":2043},{"EARLY_PHASE1":2044,"PHASE1":2046,"PHASE2":2048,"PHASE3":2050,"PHASE4":2052,"NA":2058},{"trials":2045,"activeCount":98},[],{"trials":2047,"activeCount":98},[],{"trials":2049,"activeCount":98},[],{"trials":2051,"activeCount":98},[],{"trials":2053,"activeCount":98},[2054],{"nctId":2030,"briefTitle":2031,"status":132,"phases":2055,"primaryCompletion":2033,"completion":2033,"start":2034,"enrollment":2035,"conditions":2056,"interventions":2057},[90],[2037],[2017,2039],{"trials":2059,"activeCount":98},[],{"intervention":2061,"totalTrials":169,"cells":2062},"Ketotifen Fumarate",{"EARLY_PHASE1":2063,"PHASE1":2065,"PHASE2":2067,"PHASE3":2069,"PHASE4":2071,"NA":2082},{"trials":2064,"activeCount":98},[],{"trials":2066,"activeCount":98},[],{"trials":2068,"activeCount":98},[],{"trials":2070,"activeCount":98},[],{"trials":2072,"activeCount":98},[2073],{"nctId":2074,"briefTitle":2075,"status":132,"phases":2076,"primaryCompletion":134,"completion":53,"start":2077,"enrollment":1934,"conditions":2078,"interventions":2080},"NCT05511831","The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI",[90],"2022-09-01",[2079],"ST-segment Elevation Myocardial Infarction (STEMI)",[2061,2081],"standard treatment",{"trials":2083,"activeCount":98},[],{"intervention":2081,"totalTrials":169,"cells":2085},{"EARLY_PHASE1":2086,"PHASE1":2088,"PHASE2":2090,"PHASE3":2092,"PHASE4":2094,"NA":2100},{"trials":2087,"activeCount":98},[],{"trials":2089,"activeCount":98},[],{"trials":2091,"activeCount":98},[],{"trials":2093,"activeCount":98},[],{"trials":2095,"activeCount":98},[2096],{"nctId":2074,"briefTitle":2075,"status":132,"phases":2097,"primaryCompletion":134,"completion":53,"start":2077,"enrollment":1934,"conditions":2098,"interventions":2099},[90],[2079],[2061,2081],{"trials":2101,"activeCount":98},[],{"intervention":2103,"totalTrials":169,"cells":2104},"Xingnaojing injection + Shuxuetong oral liquid",{"EARLY_PHASE1":2105,"PHASE1":2107,"PHASE2":2109,"PHASE3":2111,"PHASE4":2113,"NA":2126},{"trials":2106,"activeCount":98},[],{"trials":2108,"activeCount":98},[],{"trials":2110,"activeCount":98},[],{"trials":2112,"activeCount":98},[],{"trials":2114,"activeCount":98},[2115],{"nctId":2116,"briefTitle":2117,"status":132,"phases":2118,"primaryCompletion":2119,"completion":2120,"start":2121,"enrollment":2122,"conditions":2123,"interventions":2125},"NCT04946474","Clinical Evaluation of the Combination of Symptoms and Symptoms With General Treatment for Acute Hemorrhagic Stroke",[90],"2020-07-01","2021-09-01","2019-06-01",520,[2124],"Acute Hemorrhagic Stroke",[2103],{"trials":2127,"activeCount":98},[],{"intervention":2129,"totalTrials":169,"cells":2130},"Individualized therapy",{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2137,"PHASE4":2139,"NA":2152},{"trials":2132,"activeCount":98},[],{"trials":2134,"activeCount":98},[],{"trials":2136,"activeCount":98},[],{"trials":2138,"activeCount":98},[],{"trials":2140,"activeCount":98},[2141],{"nctId":2142,"briefTitle":2143,"status":870,"phases":2144,"primaryCompletion":2145,"completion":2146,"start":2147,"enrollment":2148,"conditions":2149,"interventions":2151},"NCT04088305","Vancomycin Dosage Strategy Based on a Trough Concentration Model",[90],"2022-05-31","2022-06-30","2019-10-01",66,[2150],"Pneumonia, Staphylococcal",[2129],{"trials":2153,"activeCount":98},[],{"intervention":2155,"totalTrials":169,"cells":2156},"without triamcinolone",{"EARLY_PHASE1":2157,"PHASE1":2159,"PHASE2":2161,"PHASE3":2163,"PHASE4":2165,"NA":2181},{"trials":2158,"activeCount":98},[],{"trials":2160,"activeCount":98},[],{"trials":2162,"activeCount":98},[],{"trials":2164,"activeCount":98},[],{"trials":2166,"activeCount":98},[2167],{"nctId":2168,"briefTitle":2169,"status":870,"phases":2170,"primaryCompletion":2171,"completion":2172,"start":2173,"enrollment":2174,"conditions":2175,"interventions":2177},"NCT05997238","Evaluation of the Effect of Triamcinolone at Different Doses on LIA During TKA",[90],"2024-02-12","2024-05-01","2023-04-25",120,[2176],"Osteoarthritis, Knee",[2155,2178,2179,2180],"20mg triamcinolone","40mg triamcinolone","80mg triamcinolone",{"trials":2182,"activeCount":98},[],{"intervention":2178,"totalTrials":169,"cells":2184},{"EARLY_PHASE1":2185,"PHASE1":2187,"PHASE2":2189,"PHASE3":2191,"PHASE4":2193,"NA":2199},{"trials":2186,"activeCount":98},[],{"trials":2188,"activeCount":98},[],{"trials":2190,"activeCount":98},[],{"trials":2192,"activeCount":98},[],{"trials":2194,"activeCount":98},[2195],{"nctId":2168,"briefTitle":2169,"status":870,"phases":2196,"primaryCompletion":2171,"completion":2172,"start":2173,"enrollment":2174,"conditions":2197,"interventions":2198},[90],[2176],[2155,2178,2179,2180],{"trials":2200,"activeCount":98},[],{"intervention":2179,"totalTrials":169,"cells":2202},{"EARLY_PHASE1":2203,"PHASE1":2205,"PHASE2":2207,"PHASE3":2209,"PHASE4":2211,"NA":2217},{"trials":2204,"activeCount":98},[],{"trials":2206,"activeCount":98},[],{"trials":2208,"activeCount":98},[],{"trials":2210,"activeCount":98},[],{"trials":2212,"activeCount":98},[2213],{"nctId":2168,"briefTitle":2169,"status":870,"phases":2214,"primaryCompletion":2171,"completion":2172,"start":2173,"enrollment":2174,"conditions":2215,"interventions":2216},[90],[2176],[2155,2178,2179,2180],{"trials":2218,"activeCount":98},[],{"intervention":2180,"totalTrials":169,"cells":2220},{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2225,"PHASE3":2227,"PHASE4":2229,"NA":2235},{"trials":2222,"activeCount":98},[],{"trials":2224,"activeCount":98},[],{"trials":2226,"activeCount":98},[],{"trials":2228,"activeCount":98},[],{"trials":2230,"activeCount":98},[2231],{"nctId":2168,"briefTitle":2169,"status":870,"phases":2232,"primaryCompletion":2171,"completion":2172,"start":2173,"enrollment":2174,"conditions":2233,"interventions":2234},[90],[2176],[2155,2178,2179,2180],{"trials":2236,"activeCount":98},[],{"intervention":717,"totalTrials":169,"cells":2238},{"EARLY_PHASE1":2239,"PHASE1":2241,"PHASE2":2243,"PHASE3":2245,"PHASE4":2247,"NA":2253},{"trials":2240,"activeCount":98},[],{"trials":2242,"activeCount":98},[],{"trials":2244,"activeCount":98},[],{"trials":2246,"activeCount":98},[],{"trials":2248,"activeCount":98},[2249],{"nctId":708,"briefTitle":709,"status":132,"phases":2250,"primaryCompletion":711,"completion":134,"start":712,"enrollment":713,"conditions":2251,"interventions":2252},[90],[715],[717,585,718,719,720],{"trials":2254,"activeCount":98},[],{"intervention":718,"totalTrials":169,"cells":2256},{"EARLY_PHASE1":2257,"PHASE1":2259,"PHASE2":2261,"PHASE3":2263,"PHASE4":2265,"NA":2271},{"trials":2258,"activeCount":98},[],{"trials":2260,"activeCount":98},[],{"trials":2262,"activeCount":98},[],{"trials":2264,"activeCount":98},[],{"trials":2266,"activeCount":98},[2267],{"nctId":708,"briefTitle":709,"status":132,"phases":2268,"primaryCompletion":711,"completion":134,"start":712,"enrollment":713,"conditions":2269,"interventions":2270},[90],[715],[717,585,718,719,720],{"trials":2272,"activeCount":98},[],{"intervention":719,"totalTrials":169,"cells":2274},{"EARLY_PHASE1":2275,"PHASE1":2277,"PHASE2":2279,"PHASE3":2281,"PHASE4":2283,"NA":2289},{"trials":2276,"activeCount":98},[],{"trials":2278,"activeCount":98},[],{"trials":2280,"activeCount":98},[],{"trials":2282,"activeCount":98},[],{"trials":2284,"activeCount":98},[2285],{"nctId":708,"briefTitle":709,"status":132,"phases":2286,"primaryCompletion":711,"completion":134,"start":712,"enrollment":713,"conditions":2287,"interventions":2288},[90],[715],[717,585,718,719,720],{"trials":2290,"activeCount":98},[],{"intervention":720,"totalTrials":169,"cells":2292},{"EARLY_PHASE1":2293,"PHASE1":2295,"PHASE2":2297,"PHASE3":2299,"PHASE4":2301,"NA":2307},{"trials":2294,"activeCount":98},[],{"trials":2296,"activeCount":98},[],{"trials":2298,"activeCount":98},[],{"trials":2300,"activeCount":98},[],{"trials":2302,"activeCount":98},[2303],{"nctId":708,"briefTitle":709,"status":132,"phases":2304,"primaryCompletion":711,"completion":134,"start":712,"enrollment":713,"conditions":2305,"interventions":2306},[90],[715],[717,585,718,719,720],{"trials":2308,"activeCount":98},[],{"intervention":2310,"totalTrials":169,"cells":2311},"Staphylococcus and Neisseria",{"EARLY_PHASE1":2312,"PHASE1":2314,"PHASE2":2316,"PHASE3":2318,"PHASE4":2320,"NA":2332},{"trials":2313,"activeCount":98},[],{"trials":2315,"activeCount":98},[],{"trials":2317,"activeCount":98},[],{"trials":2319,"activeCount":98},[],{"trials":2321,"activeCount":98},[2322],{"nctId":2323,"briefTitle":2324,"status":132,"phases":2325,"primaryCompletion":2326,"completion":2327,"start":2328,"enrollment":2329,"conditions":2330,"interventions":2331},"NCT05975788","Effect of Staphylococcus and Neisseria Tablets on Clinical Outcome Among Patients With Chronic Obstructive Pulmonary Disease",[90],"2025-02","2025-07","2023-11",750,[21],[2310],{"trials":2333,"activeCount":98},[],{"intervention":2335,"totalTrials":169,"cells":2336},"Zoledronic Acid",{"EARLY_PHASE1":2337,"PHASE1":2339,"PHASE2":2341,"PHASE3":2343,"PHASE4":2345,"NA":2356},{"trials":2338,"activeCount":98},[],{"trials":2340,"activeCount":98},[],{"trials":2342,"activeCount":98},[],{"trials":2344,"activeCount":98},[],{"trials":2346,"activeCount":98},[2347],{"nctId":2348,"briefTitle":2349,"status":132,"phases":2350,"primaryCompletion":1123,"completion":2351,"start":2352,"enrollment":288,"conditions":2353,"interventions":2355},"NCT04719650","Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid",[90],"2024-11","2021-10",[2354],"Postmenopausal Osteoporosis",[2335,2335,2335],{"trials":2357,"activeCount":98},[],{"intervention":2359,"totalTrials":169,"cells":2360},"Flupentixol melitracen",{"EARLY_PHASE1":2361,"PHASE1":2363,"PHASE2":2365,"PHASE3":2367,"PHASE4":2369,"NA":2382},{"trials":2362,"activeCount":98},[],{"trials":2364,"activeCount":98},[],{"trials":2366,"activeCount":98},[],{"trials":2368,"activeCount":98},[],{"trials":2370,"activeCount":98},[2371],{"nctId":2372,"briefTitle":2373,"status":870,"phases":2374,"primaryCompletion":2375,"completion":2376,"start":2377,"enrollment":115,"conditions":2378,"interventions":2381},"NCT04970667","Flupentixol and Melitracen Tablets in the Treatment of Emotional Disorder",[90],"2020-01-31","2020-04-30","2018-01-01",[2379,2380],"Emotional Disorder","Neurologic Disorder",[2359],{"trials":2383,"activeCount":98},[],{"intervention":2385,"totalTrials":169,"cells":2386},"Madopar monotherapy",{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2391,"PHASE3":2393,"PHASE4":2395,"NA":2408},{"trials":2388,"activeCount":98},[],{"trials":2390,"activeCount":98},[],{"trials":2392,"activeCount":98},[],{"trials":2394,"activeCount":98},[],{"trials":2396,"activeCount":98},[2397],{"nctId":2398,"briefTitle":2399,"status":132,"phases":2400,"primaryCompletion":2401,"completion":2401,"start":2377,"enrollment":2402,"conditions":2403,"interventions":2406},"NCT04968613","Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease",[90],"2021-12-31",150,[2404,2405],"Parkinson Disease","Memory Impairment",[2385,2407],"senfrol monotherapy",{"trials":2409,"activeCount":98},[],{"intervention":2407,"totalTrials":169,"cells":2411},{"EARLY_PHASE1":2412,"PHASE1":2414,"PHASE2":2416,"PHASE3":2418,"PHASE4":2420,"NA":2426},{"trials":2413,"activeCount":98},[],{"trials":2415,"activeCount":98},[],{"trials":2417,"activeCount":98},[],{"trials":2419,"activeCount":98},[],{"trials":2421,"activeCount":98},[2422],{"nctId":2398,"briefTitle":2399,"status":132,"phases":2423,"primaryCompletion":2401,"completion":2401,"start":2377,"enrollment":2402,"conditions":2424,"interventions":2425},[90],[2404,2405],[2385,2407],{"trials":2427,"activeCount":98},[],{"intervention":2429,"totalTrials":169,"cells":2430},"Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin",{"EARLY_PHASE1":2431,"PHASE1":2433,"PHASE2":2435,"PHASE3":2437,"PHASE4":2439,"NA":2449},{"trials":2432,"activeCount":98},[],{"trials":2434,"activeCount":98},[],{"trials":2436,"activeCount":98},[],{"trials":2438,"activeCount":98},[],{"trials":2440,"activeCount":98},[2441],{"nctId":2442,"briefTitle":2443,"status":132,"phases":2444,"primaryCompletion":135,"completion":53,"start":2445,"enrollment":1934,"conditions":2446,"interventions":2448},"NCT05747768","A Clinical Study to Evaluate the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Healthy Volunteers and Renal Impairment Patients",[90],"2022-07-15",[2447],"Chronic Kidney Disease",[2429],{"trials":2450,"activeCount":98},[],{"intervention":2452,"totalTrials":169,"cells":2453},"The combinations of 10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin were administered to diabetic patients on an empty stomach.",{"EARLY_PHASE1":2454,"PHASE1":2456,"PHASE2":2458,"PHASE3":2460,"PHASE4":2462,"NA":2473},{"trials":2455,"activeCount":98},[],{"trials":2457,"activeCount":98},[],{"trials":2459,"activeCount":98},[],{"trials":2461,"activeCount":98},[],{"trials":2463,"activeCount":98},[2464],{"nctId":2465,"briefTitle":2466,"status":132,"phases":2467,"primaryCompletion":112,"completion":112,"start":2468,"enrollment":2469,"conditions":2470,"interventions":2472},"NCT06273215","Evaluation of the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Diabetic Patients",[90],"2023-03-05",48,[2471],"Diabetes",[2452],{"trials":2474,"activeCount":98},[],{"intervention":2476,"totalTrials":169,"cells":2477},"Levosimendan",{"EARLY_PHASE1":2478,"PHASE1":2480,"PHASE2":2482,"PHASE3":2484,"PHASE4":2486,"NA":2497},{"trials":2479,"activeCount":98},[],{"trials":2481,"activeCount":98},[],{"trials":2483,"activeCount":98},[],{"trials":2485,"activeCount":98},[],{"trials":2487,"activeCount":98},[2488],{"nctId":2489,"briefTitle":2490,"status":132,"phases":2491,"primaryCompletion":53,"completion":53,"start":2492,"enrollment":1934,"conditions":2493,"interventions":2495},"NCT05956431","RCT Study of Levosimendan Improving Prognosis of Cardiac Arrest",[90],"2023-08-01",[2494],"Heart Arrest",[2476,2496],"physiological saline",{"trials":2498,"activeCount":98},[],{"intervention":2496,"totalTrials":169,"cells":2500},{"EARLY_PHASE1":2501,"PHASE1":2503,"PHASE2":2505,"PHASE3":2507,"PHASE4":2509,"NA":2515},{"trials":2502,"activeCount":98},[],{"trials":2504,"activeCount":98},[],{"trials":2506,"activeCount":98},[],{"trials":2508,"activeCount":98},[],{"trials":2510,"activeCount":98},[2511],{"nctId":2489,"briefTitle":2490,"status":132,"phases":2512,"primaryCompletion":53,"completion":53,"start":2492,"enrollment":1934,"conditions":2513,"interventions":2514},[90],[2494],[2476,2496],{"trials":2516,"activeCount":98},[],{"intervention":2518,"totalTrials":169,"cells":2519},"Pravastatin Sodium 80 MG",{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2524,"PHASE3":2526,"PHASE4":2528,"NA":2539},{"trials":2521,"activeCount":98},[],{"trials":2523,"activeCount":98},[],{"trials":2525,"activeCount":98},[],{"trials":2527,"activeCount":98},[],{"trials":2529,"activeCount":98},[2530],{"nctId":2531,"briefTitle":2532,"status":132,"phases":2533,"primaryCompletion":2534,"completion":2535,"start":2534,"enrollment":2536,"conditions":2537,"interventions":2538},"NCT04719481","Pravastatin Reduces Acute Phase Response of Zoledronic Acid",[90],"2021-11","2022-04",110,[2354],[2518],{"trials":2540,"activeCount":98},[],{"intervention":2542,"totalTrials":169,"cells":2543},"ticagrelor + ASA",{"EARLY_PHASE1":2544,"PHASE1":2546,"PHASE2":2548,"PHASE3":2550,"PHASE4":2552,"NA":2566},{"trials":2545,"activeCount":98},[],{"trials":2547,"activeCount":98},[],{"trials":2549,"activeCount":98},[],{"trials":2551,"activeCount":98},[],{"trials":2553,"activeCount":98},[2554],{"nctId":2555,"briefTitle":2556,"status":870,"phases":2557,"primaryCompletion":2558,"completion":2559,"start":2560,"enrollment":2561,"conditions":2562,"interventions":2565},"NCT04962451","Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke",[90],"2019-09-30","2019-10-31","2017-09-01",13000,[2563,2564],"Cerebrovascular Accident","Cerebrovascular Accident, Acute",[2542],{"trials":2567,"activeCount":98},[],{"intervention":2569,"totalTrials":169,"cells":2570},"Shexiang Tongxin Dropping Pills + routine treatment",{"EARLY_PHASE1":2571,"PHASE1":2573,"PHASE2":2575,"PHASE3":2577,"PHASE4":2579,"NA":2591},{"trials":2572,"activeCount":98},[],{"trials":2574,"activeCount":98},[],{"trials":2576,"activeCount":98},[],{"trials":2578,"activeCount":98},[],{"trials":2580,"activeCount":98},[2581],{"nctId":2582,"briefTitle":2583,"status":132,"phases":2584,"primaryCompletion":2585,"completion":2586,"start":2587,"enrollment":1934,"conditions":2588,"interventions":2590},"NCT04952259","Effect of Shexiang Tongxin Dropping Pills on Microcirculation in Patients With AMI",[90],"2022-07-31","2023-07-31","2021-08-01",[2589],"Acute Myocardial Infarction",[2569],{"trials":2592,"activeCount":98},[],{"intervention":2594,"totalTrials":169,"cells":2595},"Minodronate",{"EARLY_PHASE1":2596,"PHASE1":2598,"PHASE2":2600,"PHASE3":2602,"PHASE4":2604,"NA":2616},{"trials":2597,"activeCount":98},[],{"trials":2599,"activeCount":98},[],{"trials":2601,"activeCount":98},[],{"trials":2603,"activeCount":98},[],{"trials":2605,"activeCount":98},[2606],{"nctId":2607,"briefTitle":2608,"status":132,"phases":2609,"primaryCompletion":134,"completion":2610,"start":2611,"enrollment":2612,"conditions":2613,"interventions":2614},"NCT05645289","Efficacy and Safety of Minodronate in Patients With Low Back Pain",[90],"2024-04-01","2023-01-01",72,[2354],[2594,2615],"Alendronate",{"trials":2617,"activeCount":98},[],{"intervention":2615,"totalTrials":169,"cells":2619},{"EARLY_PHASE1":2620,"PHASE1":2622,"PHASE2":2624,"PHASE3":2626,"PHASE4":2628,"NA":2634},{"trials":2621,"activeCount":98},[],{"trials":2623,"activeCount":98},[],{"trials":2625,"activeCount":98},[],{"trials":2627,"activeCount":98},[],{"trials":2629,"activeCount":98},[2630],{"nctId":2607,"briefTitle":2608,"status":132,"phases":2631,"primaryCompletion":134,"completion":2610,"start":2611,"enrollment":2612,"conditions":2632,"interventions":2633},[90],[2354],[2594,2615],{"trials":2635,"activeCount":98},[],{"intervention":2637,"totalTrials":169,"cells":2638},"Tafamidis Pill",{"EARLY_PHASE1":2639,"PHASE1":2641,"PHASE2":2643,"PHASE3":2645,"PHASE4":2647,"NA":2658},{"trials":2640,"activeCount":98},[],{"trials":2642,"activeCount":98},[],{"trials":2644,"activeCount":98},[],{"trials":2646,"activeCount":98},[],{"trials":2648,"activeCount":98},[2649],{"nctId":2650,"briefTitle":2651,"status":132,"phases":2652,"primaryCompletion":2653,"completion":2654,"start":1988,"enrollment":767,"conditions":2655,"interventions":2657},"NCT04963985","The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients",[90],"2022-06-01","2023-06-01",[2656],"Transthyretin Amyloidosis",[2637],{"trials":2659,"activeCount":98},[],{"intervention":2661,"totalTrials":169,"cells":2662},"Diquafosol",{"EARLY_PHASE1":2663,"PHASE1":2665,"PHASE2":2667,"PHASE3":2669,"PHASE4":2671,"NA":2686},{"trials":2664,"activeCount":98},[],{"trials":2666,"activeCount":98},[],{"trials":2668,"activeCount":98},[],{"trials":2670,"activeCount":98},[],{"trials":2672,"activeCount":98},[2673],{"nctId":2674,"briefTitle":2675,"status":132,"phases":2676,"primaryCompletion":2677,"completion":2678,"start":2679,"enrollment":2680,"conditions":2681,"interventions":2685},"NCT04668118","The Effect of 3% Diquafosol Ophthalmic Solution on Visual Display Terminal-associated Dry Eye",[90],"2022-10-01","2023-03-25","2021-02-01",68,[2682,2683,2684],"Dry Eye Syndromes","Computer Vision Syndrome","Asthenopia",[2661],{"trials":2687,"activeCount":98},[],{"intervention":2689,"totalTrials":169,"cells":2690},"nicorandil",{"EARLY_PHASE1":2691,"PHASE1":2693,"PHASE2":2695,"PHASE3":2697,"PHASE4":2699,"NA":2711},{"trials":2692,"activeCount":98},[],{"trials":2694,"activeCount":98},[],{"trials":2696,"activeCount":98},[],{"trials":2698,"activeCount":98},[],{"trials":2700,"activeCount":98},[2701],{"nctId":2702,"briefTitle":2703,"status":870,"phases":2704,"primaryCompletion":2705,"completion":2705,"start":2706,"enrollment":2707,"conditions":2708,"interventions":2710},"NCT05087797","The Effect of Nicorandil on Left Ventricular Myocardial Strain in Patients With Coronary Chronic Total Occlusion",[90],"2020-07-08","2019-04-08",61,[2709],"Coronary Artery Disease",[2689],{"trials":2712,"activeCount":98},[],{"intervention":2714,"totalTrials":126,"cells":2715},"Riluzole",{"EARLY_PHASE1":2716,"PHASE1":2727,"PHASE2":2729,"PHASE3":2731,"PHASE4":2743,"NA":2745},{"trials":2717,"activeCount":98},[2718],{"nctId":2719,"briefTitle":2720,"status":870,"phases":2721,"primaryCompletion":2722,"completion":2722,"start":2723,"enrollment":375,"conditions":2724,"interventions":2725},"NCT04454840","Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral Sclerosis",[86],"2019-05-01","2016-05-01",[15],[2726,2714],"Plasma from healthy young people treatment + Riluzole",{"trials":2728,"activeCount":98},[],{"trials":2730,"activeCount":98},[],{"trials":2732,"activeCount":98},[2733],{"nctId":2734,"briefTitle":2735,"status":132,"phases":2736,"primaryCompletion":2401,"completion":2737,"start":2738,"enrollment":2739,"conditions":2740,"interventions":2741},"NCT04950933","The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules",[88,89],"2022-12-31","2020-06-01",144,[15],[2742,2714],"Huolingshengji Granules",{"trials":2744,"activeCount":98},[],{"trials":2746,"activeCount":98},[],{"intervention":2748,"totalTrials":169,"cells":2749},"Y-2 sublingual",{"EARLY_PHASE1":2750,"PHASE1":2752,"PHASE2":2754,"PHASE3":2756,"PHASE4":2769,"NA":2771},{"trials":2751,"activeCount":98},[],{"trials":2753,"activeCount":98},[],{"trials":2755,"activeCount":98},[],{"trials":2757,"activeCount":98},[2758],{"nctId":2759,"briefTitle":2760,"status":870,"phases":2761,"primaryCompletion":2762,"completion":2763,"start":2764,"enrollment":2765,"conditions":2766,"interventions":2767},"NCT04950920","Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke",[89],"2022-08-10","2022-11-14","2021-06-28",914,[33],[2748,2768],"d-borneol",{"trials":2770,"activeCount":98},[],{"trials":2772,"activeCount":98},[],{"intervention":2768,"totalTrials":169,"cells":2774},{"EARLY_PHASE1":2775,"PHASE1":2777,"PHASE2":2779,"PHASE3":2781,"PHASE4":2787,"NA":2789},{"trials":2776,"activeCount":98},[],{"trials":2778,"activeCount":98},[],{"trials":2780,"activeCount":98},[],{"trials":2782,"activeCount":98},[2783],{"nctId":2759,"briefTitle":2760,"status":870,"phases":2784,"primaryCompletion":2762,"completion":2763,"start":2764,"enrollment":2765,"conditions":2785,"interventions":2786},[89],[33],[2748,2768],{"trials":2788,"activeCount":98},[],{"trials":2790,"activeCount":98},[],{"intervention":2792,"totalTrials":169,"cells":2793},"sumatriptan 85mg and naproxen sodium 500mg",{"EARLY_PHASE1":2794,"PHASE1":2796,"PHASE2":2798,"PHASE3":2800,"PHASE4":2810,"NA":2812},{"trials":2795,"activeCount":98},[],{"trials":2797,"activeCount":98},[],{"trials":2799,"activeCount":98},[],{"trials":2801,"activeCount":98},[2802],{"nctId":2803,"briefTitle":2804,"status":132,"phases":2805,"primaryCompletion":2033,"completion":2033,"start":2806,"enrollment":943,"conditions":2807,"interventions":2809},"NCT04948164","Study of Sumatriptan Naproxen Sodium Succinate Tablets for the Treatment of Acute Migraine Attacks",[89],"2018-08-01",[2808],"Migraine in Adults",[2792],{"trials":2811,"activeCount":98},[],{"trials":2813,"activeCount":98},[],{"intervention":2815,"totalTrials":169,"cells":2816},"Prescription of traditional Chinese Medicine named Er Zhi Wan combined with Si Wu Tang",{"EARLY_PHASE1":2817,"PHASE1":2819,"PHASE2":2821,"PHASE3":2823,"PHASE4":2835,"NA":2837},{"trials":2818,"activeCount":98},[],{"trials":2820,"activeCount":98},[],{"trials":2822,"activeCount":98},[],{"trials":2824,"activeCount":98},[2825],{"nctId":2826,"briefTitle":2827,"status":132,"phases":2828,"primaryCompletion":2829,"completion":2829,"start":2830,"enrollment":2831,"conditions":2832,"interventions":2833},"NCT04935073","Traditional Chinese Medicine Herbs in the Freeze-all IVF Cycle",[89],"2022-12-30","2021-06-15",90,[183],[2815,2834],"Recombinant Human Follitropin Alfa for Injection、Fructose Injection、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder for",{"trials":2836,"activeCount":98},[],{"trials":2838,"activeCount":98},[],{"intervention":2834,"totalTrials":169,"cells":2840},{"EARLY_PHASE1":2841,"PHASE1":2843,"PHASE2":2845,"PHASE3":2847,"PHASE4":2853,"NA":2855},{"trials":2842,"activeCount":98},[],{"trials":2844,"activeCount":98},[],{"trials":2846,"activeCount":98},[],{"trials":2848,"activeCount":98},[2849],{"nctId":2826,"briefTitle":2827,"status":132,"phases":2850,"primaryCompletion":2829,"completion":2829,"start":2830,"enrollment":2831,"conditions":2851,"interventions":2852},[89],[183],[2815,2834],{"trials":2854,"activeCount":98},[],{"trials":2856,"activeCount":98},[],{"intervention":2858,"totalTrials":169,"cells":2859},"Er Zhi Wan combined with Si Wu Tang",{"EARLY_PHASE1":2860,"PHASE1":2862,"PHASE2":2864,"PHASE3":2866,"PHASE4":2876,"NA":2878},{"trials":2861,"activeCount":98},[],{"trials":2863,"activeCount":98},[],{"trials":2865,"activeCount":98},[],{"trials":2867,"activeCount":98},[2868],{"nctId":2869,"briefTitle":2870,"status":132,"phases":2871,"primaryCompletion":2829,"completion":2829,"start":2872,"enrollment":713,"conditions":2873,"interventions":2874},"NCT04842825","Sequential Therapy of TCM Herbs to Improve the Success Rate of IVF-ET in Diminished Ovarian Reserve Patients",[89],"2021-04-15",[183],[2858,2875],"Recombinant Human Follitropin Alfa 、Fructose 、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder",{"trials":2877,"activeCount":98},[],{"trials":2879,"activeCount":98},[],{"intervention":2875,"totalTrials":169,"cells":2881},{"EARLY_PHASE1":2882,"PHASE1":2884,"PHASE2":2886,"PHASE3":2888,"PHASE4":2894,"NA":2896},{"trials":2883,"activeCount":98},[],{"trials":2885,"activeCount":98},[],{"trials":2887,"activeCount":98},[],{"trials":2889,"activeCount":98},[2890],{"nctId":2869,"briefTitle":2870,"status":132,"phases":2891,"primaryCompletion":2829,"completion":2829,"start":2872,"enrollment":713,"conditions":2892,"interventions":2893},[89],[183],[2858,2875],{"trials":2895,"activeCount":98},[],{"trials":2897,"activeCount":98},[],{"intervention":2899,"totalTrials":169,"cells":2900},"Medical prescription before ovulation",{"EARLY_PHASE1":2901,"PHASE1":2903,"PHASE2":2905,"PHASE3":2907,"PHASE4":2920,"NA":2922},{"trials":2902,"activeCount":98},[],{"trials":2904,"activeCount":98},[],{"trials":2906,"activeCount":98},[],{"trials":2908,"activeCount":98},[2909],{"nctId":2910,"briefTitle":2911,"status":132,"phases":2912,"primaryCompletion":2913,"completion":2913,"start":2914,"enrollment":2915,"conditions":2916,"interventions":2918},"NCT05577455","Efficacy of Traditional Chinese Medicine on Ameliorating IVF-ET Outcomes of Diminished Ovarian Reserve Patients",[89],"2024-12-30","2022-11-10",266,[2917,183],"Diminished Ovarian Reserve",[2899,2919],"Medical prescription after ovulation",{"trials":2921,"activeCount":98},[],{"trials":2923,"activeCount":98},[],{"intervention":2919,"totalTrials":169,"cells":2925},{"EARLY_PHASE1":2926,"PHASE1":2928,"PHASE2":2930,"PHASE3":2932,"PHASE4":2938,"NA":2940},{"trials":2927,"activeCount":98},[],{"trials":2929,"activeCount":98},[],{"trials":2931,"activeCount":98},[],{"trials":2933,"activeCount":98},[2934],{"nctId":2910,"briefTitle":2911,"status":132,"phases":2935,"primaryCompletion":2913,"completion":2913,"start":2914,"enrollment":2915,"conditions":2936,"interventions":2937},[89],[2917,183],[2899,2919],{"trials":2939,"activeCount":98},[],{"trials":2941,"activeCount":98},[],{"intervention":2943,"totalTrials":169,"cells":2944},"LY03003",{"EARLY_PHASE1":2945,"PHASE1":2947,"PHASE2":2949,"PHASE3":2951,"PHASE4":2962,"NA":2964},{"trials":2946,"activeCount":98},[],{"trials":2948,"activeCount":98},[],{"trials":2950,"activeCount":98},[],{"trials":2952,"activeCount":98},[2953],{"nctId":2954,"briefTitle":2955,"status":870,"phases":2956,"primaryCompletion":2957,"completion":2957,"start":2806,"enrollment":2958,"conditions":2959,"interventions":2961},"NCT04455555","Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease",[89],"2019-02-01",294,[2960],"Parkinson's Disease",[2943],{"trials":2963,"activeCount":98},[],{"trials":2965,"activeCount":98},[],{"intervention":2967,"totalTrials":169,"cells":2968},"Umbilical cord blood mononuclear cell gel（MNC）",{"EARLY_PHASE1":2969,"PHASE1":2971,"PHASE2":2973,"PHASE3":2975,"PHASE4":2986,"NA":2988},{"trials":2970,"activeCount":98},[],{"trials":2972,"activeCount":98},[],{"trials":2974,"activeCount":98},[],{"trials":2976,"activeCount":98},[2977],{"nctId":2978,"briefTitle":2979,"status":132,"phases":2980,"primaryCompletion":134,"completion":53,"start":2981,"enrollment":511,"conditions":2982,"interventions":2984},"NCT04689425","Umbilical Cord Blood Mononuclear Cell Gel in the Treatment of Refractory Diabetic Foot Ulcer",[89],"2021-03-30",[2983],"Diabetic Foot Ulcer",[2967,2985],"The platelet rich plasma（PRP）",{"trials":2987,"activeCount":98},[],{"trials":2989,"activeCount":98},[],{"intervention":2985,"totalTrials":169,"cells":2991},{"EARLY_PHASE1":2992,"PHASE1":2994,"PHASE2":2996,"PHASE3":2998,"PHASE4":3004,"NA":3006},{"trials":2993,"activeCount":98},[],{"trials":2995,"activeCount":98},[],{"trials":2997,"activeCount":98},[],{"trials":2999,"activeCount":98},[3000],{"nctId":2978,"briefTitle":2979,"status":132,"phases":3001,"primaryCompletion":134,"completion":53,"start":2981,"enrollment":511,"conditions":3002,"interventions":3003},[89],[2983],[2967,2985],{"trials":3005,"activeCount":98},[],{"trials":3007,"activeCount":98},[],{"intervention":3009,"totalTrials":169,"cells":3010},"Trimetazidine",{"EARLY_PHASE1":3011,"PHASE1":3013,"PHASE2":3015,"PHASE3":3017,"PHASE4":3028,"NA":3030},{"trials":3012,"activeCount":98},[],{"trials":3014,"activeCount":98},[],{"trials":3016,"activeCount":98},[],{"trials":3018,"activeCount":98},[3019],{"nctId":3020,"briefTitle":3021,"status":132,"phases":3022,"primaryCompletion":3023,"completion":1933,"start":3024,"enrollment":1734,"conditions":3025,"interventions":3027},"NCT04939857","Effect of Trimetazidine on Radiotherapy-induced Heart Damage.",[88,89],"2022-07-30","2021-06-25",[3026],"Cardiotoxicity",[3009],{"trials":3029,"activeCount":98},[],{"trials":3031,"activeCount":98},[],{"intervention":2742,"totalTrials":169,"cells":3033},{"EARLY_PHASE1":3034,"PHASE1":3036,"PHASE2":3038,"PHASE3":3040,"PHASE4":3046,"NA":3048},{"trials":3035,"activeCount":98},[],{"trials":3037,"activeCount":98},[],{"trials":3039,"activeCount":98},[],{"trials":3041,"activeCount":98},[3042],{"nctId":2734,"briefTitle":2735,"status":132,"phases":3043,"primaryCompletion":2401,"completion":2737,"start":2738,"enrollment":2739,"conditions":3044,"interventions":3045},[88,89],[15],[2742,2714],{"trials":3047,"activeCount":98},[],{"trials":3049,"activeCount":98},[],{"intervention":3051,"totalTrials":169,"cells":3052},"surgical robot",{"EARLY_PHASE1":3053,"PHASE1":3055,"PHASE2":3057,"PHASE3":3059,"PHASE4":3071,"NA":3073},{"trials":3054,"activeCount":98},[],{"trials":3056,"activeCount":98},[],{"trials":3058,"activeCount":98},[],{"trials":3060,"activeCount":98},[3061],{"nctId":3062,"briefTitle":3063,"status":870,"phases":3064,"primaryCompletion":3065,"completion":3065,"start":2560,"enrollment":1934,"conditions":3066,"interventions":3069},"NCT04956588","Evaluation of the Safety and Efficacy of Smart Orthopedic Minimally Invasive Surgical Systems for Spinal Surgery",[89],"2018-12-31",[3067,3068],"Spine Disease","Spinal Fractures",[3051,3070],"controlled approach",{"trials":3072,"activeCount":98},[],{"trials":3074,"activeCount":98},[],{"intervention":3070,"totalTrials":169,"cells":3076},{"EARLY_PHASE1":3077,"PHASE1":3079,"PHASE2":3081,"PHASE3":3083,"PHASE4":3089,"NA":3091},{"trials":3078,"activeCount":98},[],{"trials":3080,"activeCount":98},[],{"trials":3082,"activeCount":98},[],{"trials":3084,"activeCount":98},[3085],{"nctId":3062,"briefTitle":3063,"status":870,"phases":3086,"primaryCompletion":3065,"completion":3065,"start":2560,"enrollment":1934,"conditions":3087,"interventions":3088},[89],[3067,3068],[3051,3070],{"trials":3090,"activeCount":98},[],{"trials":3092,"activeCount":98},[],{"intervention":3094,"totalTrials":169,"cells":3095},"it-hMSC",{"EARLY_PHASE1":3096,"PHASE1":3098,"PHASE2":3100,"PHASE3":3110,"PHASE4":3112,"NA":3114},{"trials":3097,"activeCount":98},[],{"trials":3099,"activeCount":98},[],{"trials":3101,"activeCount":98},[3102],{"nctId":3103,"briefTitle":3104,"status":132,"phases":3105,"primaryCompletion":3106,"completion":2611,"start":3107,"enrollment":1934,"conditions":3108,"interventions":3109},"NCT04953663","Clinical Plan of Ischemic Stroke",[87,88],"2022-01-01","2021-01-01",[33],[3094],{"trials":3111,"activeCount":98},[],{"trials":3113,"activeCount":98},[],{"trials":3115,"activeCount":98},[],{"intervention":3117,"totalTrials":169,"cells":3118},"proactive Anti-VEGF (conbercept) use",{"EARLY_PHASE1":3119,"PHASE1":3121,"PHASE2":3123,"PHASE3":3136,"PHASE4":3138,"NA":3140},{"trials":3120,"activeCount":98},[],{"trials":3122,"activeCount":98},[],{"trials":3124,"activeCount":98},[3125],{"nctId":3126,"briefTitle":3127,"status":132,"phases":3128,"primaryCompletion":3129,"completion":3130,"start":3131,"enrollment":1734,"conditions":3132,"interventions":3134},"NCT05642793","Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients",[88],"2023-09-30","2024-03-01","2022-04-01",[3133],"Proliferative Diabetic Retinopathy",[3117,3135],"passive Anti-VEGF (conbercept) use",{"trials":3137,"activeCount":98},[],{"trials":3139,"activeCount":98},[],{"trials":3141,"activeCount":98},[],{"intervention":3135,"totalTrials":169,"cells":3143},{"EARLY_PHASE1":3144,"PHASE1":3146,"PHASE2":3148,"PHASE3":3154,"PHASE4":3156,"NA":3158},{"trials":3145,"activeCount":98},[],{"trials":3147,"activeCount":98},[],{"trials":3149,"activeCount":98},[3150],{"nctId":3126,"briefTitle":3127,"status":132,"phases":3151,"primaryCompletion":3129,"completion":3130,"start":3131,"enrollment":1734,"conditions":3152,"interventions":3153},[88],[3133],[3117,3135],{"trials":3155,"activeCount":98},[],{"trials":3157,"activeCount":98},[],{"trials":3159,"activeCount":98},[],{"intervention":3161,"totalTrials":169,"cells":3162},"Cadonilimab",{"EARLY_PHASE1":3163,"PHASE1":3165,"PHASE2":3167,"PHASE3":3183,"PHASE4":3185,"NA":3187},{"trials":3164,"activeCount":98},[],{"trials":3166,"activeCount":98},[],{"trials":3168,"activeCount":98},[3169],{"nctId":3170,"briefTitle":3171,"status":132,"phases":3172,"primaryCompletion":3173,"completion":3174,"start":3175,"enrollment":1934,"conditions":3176,"interventions":3182},"NCT05915481","Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors",[87,88],"2024-06-21","2025-06-21","2023-06-21",[3177,3178,3179,3180,3181],"Advanced Solid Tumor","Stereotactic Body Radiotherapy","Immune Checkpoint Inhibitor","Safety","Efficacy",[3161],{"trials":3184,"activeCount":98},[],{"trials":3186,"activeCount":98},[],{"trials":3188,"activeCount":98},[],{"intervention":3190,"totalTrials":169,"cells":3191},"FAM-NP41",{"EARLY_PHASE1":3192,"PHASE1":3194,"PHASE2":3196,"PHASE3":3206,"PHASE4":3208,"NA":3210},{"trials":3193,"activeCount":98},[],{"trials":3195,"activeCount":98},[],{"trials":3197,"activeCount":98},[3198],{"nctId":3199,"briefTitle":3200,"status":132,"phases":3201,"primaryCompletion":3202,"completion":134,"start":3106,"enrollment":511,"conditions":3203,"interventions":3205},"NCT05043519","Phase I\u002FII Clinical Trial of NP41 for Cranial Nerve Fluorescence Imaging",[87,88],"2023-08-31",[3204],"Cranial Nerve Injuries",[3190],{"trials":3207,"activeCount":98},[],{"trials":3209,"activeCount":98},[],{"trials":3211,"activeCount":98},[],{"intervention":821,"totalTrials":169,"cells":3213},{"EARLY_PHASE1":3214,"PHASE1":3216,"PHASE2":3218,"PHASE3":3224,"PHASE4":3226,"NA":3228},{"trials":3215,"activeCount":98},[],{"trials":3217,"activeCount":98},[],{"trials":3219,"activeCount":98},[3220],{"nctId":813,"briefTitle":814,"status":132,"phases":3221,"primaryCompletion":816,"completion":816,"start":135,"enrollment":817,"conditions":3222,"interventions":3223},[88],[819],[734,821],{"trials":3225,"activeCount":98},[],{"trials":3227,"activeCount":98},[],{"trials":3229,"activeCount":98},[],{"intervention":3231,"totalTrials":169,"cells":3232},"Luveris",{"EARLY_PHASE1":3233,"PHASE1":3235,"PHASE2":3237,"PHASE3":3248,"PHASE4":3250,"NA":3252},{"trials":3234,"activeCount":98},[],{"trials":3236,"activeCount":98},[],{"trials":3238,"activeCount":98},[3239],{"nctId":3240,"briefTitle":3241,"status":132,"phases":3242,"primaryCompletion":3243,"completion":3244,"start":3245,"enrollment":2402,"conditions":3246,"interventions":3247},"NCT01029470","To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation",[88],"2010-10","2011-03","2009-12",[166],[3231],{"trials":3249,"activeCount":98},[],{"trials":3251,"activeCount":98},[],{"trials":3253,"activeCount":98},[],{"intervention":3255,"totalTrials":169,"cells":3256},"PD-1 antibody",{"EARLY_PHASE1":3257,"PHASE1":3259,"PHASE2":3261,"PHASE3":3270,"PHASE4":3272,"NA":3274},{"trials":3258,"activeCount":98},[],{"trials":3260,"activeCount":98},[],{"trials":3262,"activeCount":98},[3263],{"nctId":3264,"briefTitle":3265,"status":132,"phases":3266,"primaryCompletion":2401,"completion":2737,"start":3267,"enrollment":556,"conditions":3268,"interventions":3269},"NCT04368273","Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.",[87,88],"2020-05-08",[583],[3255],{"trials":3271,"activeCount":98},[],{"trials":3273,"activeCount":98},[],{"trials":3275,"activeCount":98},[],{"intervention":3277,"totalTrials":169,"cells":3278},"sofadil【Neu2000KW】",{"EARLY_PHASE1":3279,"PHASE1":3281,"PHASE2":3283,"PHASE3":3294,"PHASE4":3296,"NA":3298},{"trials":3280,"activeCount":98},[],{"trials":3282,"activeCount":98},[],{"trials":3284,"activeCount":98},[3285],{"nctId":3286,"briefTitle":3287,"status":870,"phases":3288,"primaryCompletion":2377,"completion":2377,"start":3289,"enrollment":3290,"conditions":3291,"interventions":3292},"NCT04453800","The Efficacy and Safety of Sofadil for Injection in the Treatment of Acute Ischemic Stroke",[88],"2016-10-01",236,[2037],[3277,3293,3293],"Sofadil",{"trials":3295,"activeCount":98},[],{"trials":3297,"activeCount":98},[],{"trials":3299,"activeCount":98},[],{"intervention":3293,"totalTrials":169,"cells":3301},{"EARLY_PHASE1":3302,"PHASE1":3304,"PHASE2":3306,"PHASE3":3312,"PHASE4":3314,"NA":3316},{"trials":3303,"activeCount":98},[],{"trials":3305,"activeCount":98},[],{"trials":3307,"activeCount":98},[3308],{"nctId":3286,"briefTitle":3287,"status":870,"phases":3309,"primaryCompletion":2377,"completion":2377,"start":3289,"enrollment":3290,"conditions":3310,"interventions":3311},[88],[2037],[3277,3293,3293],{"trials":3313,"activeCount":98},[],{"trials":3315,"activeCount":98},[],{"trials":3317,"activeCount":98},[],{"intervention":3319,"totalTrials":169,"cells":3320},"recombinant teriparatide for",{"EARLY_PHASE1":3321,"PHASE1":3323,"PHASE2":3325,"PHASE3":3334,"PHASE4":3336,"NA":3338},{"trials":3322,"activeCount":98},[],{"trials":3324,"activeCount":98},[],{"trials":3326,"activeCount":98},[3327],{"nctId":3328,"briefTitle":3329,"status":132,"phases":3330,"primaryCompletion":114,"completion":135,"start":1988,"enrollment":1734,"conditions":3331,"interventions":3333},"NCT04473989","Weekly Use of Teriparatide to Accelerate Healing of Distal Radius Fracture",[88],[3332],"Colles' Fracture",[3319],{"trials":3335,"activeCount":98},[],{"trials":3337,"activeCount":98},[],{"trials":3339,"activeCount":98},[],{"intervention":3341,"totalTrials":169,"cells":3342},"Fasudil",{"EARLY_PHASE1":3343,"PHASE1":3345,"PHASE2":3347,"PHASE3":3358,"PHASE4":3360,"NA":3362},{"trials":3344,"activeCount":98},[],{"trials":3346,"activeCount":98},[],{"trials":3348,"activeCount":98},[3349],{"nctId":3350,"briefTitle":3351,"status":132,"phases":3352,"primaryCompletion":3353,"completion":3354,"start":3355,"enrollment":767,"conditions":3356,"interventions":3357},"NCT01935518","A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)",[88],"2015-03","2015-05","2013-09",[15],[3341],{"trials":3359,"activeCount":98},[],{"trials":3361,"activeCount":98},[],{"trials":3363,"activeCount":98},[],{"intervention":3365,"totalTrials":169,"cells":3366},"methylcobalamin",{"EARLY_PHASE1":3367,"PHASE1":3369,"PHASE2":3371,"PHASE3":3383,"PHASE4":3385,"NA":3387},{"trials":3368,"activeCount":98},[],{"trials":3370,"activeCount":98},[],{"trials":3372,"activeCount":98},[3373],{"nctId":3374,"briefTitle":3375,"status":132,"phases":3376,"primaryCompletion":3377,"completion":3378,"start":3379,"enrollment":556,"conditions":3380,"interventions":3382},"NCT04372316","A Randomized Controlled Trial of Mecobalamin Injection and Tablet Treatment Efficacy on Mild to Moderate Diabetic Peripheral Neuropathy",[88],"2020-07","2021-12","2017-12-25",[3381],"Diabetic Neuropathies",[3365],{"trials":3384,"activeCount":98},[],{"trials":3386,"activeCount":98},[],{"trials":3388,"activeCount":98},[],{"intervention":3390,"totalTrials":169,"cells":3391},"Anlotinib Hydrochloride",{"EARLY_PHASE1":3392,"PHASE1":3394,"PHASE2":3396,"PHASE3":3408,"PHASE4":3410,"NA":3412},{"trials":3393,"activeCount":98},[],{"trials":3395,"activeCount":98},[],{"trials":3397,"activeCount":98},[3398],{"nctId":3399,"briefTitle":3400,"status":132,"phases":3401,"primaryCompletion":3402,"completion":1190,"start":3403,"enrollment":3404,"conditions":3405,"interventions":3406},"NCT05485350","Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)",[88],"2023-09-21","2022-09-12",32,[1193],[3390,3407],"penpulimab",{"trials":3409,"activeCount":98},[],{"trials":3411,"activeCount":98},[],{"trials":3413,"activeCount":98},[],{"intervention":3407,"totalTrials":169,"cells":3415},{"EARLY_PHASE1":3416,"PHASE1":3418,"PHASE2":3420,"PHASE3":3426,"PHASE4":3428,"NA":3430},{"trials":3417,"activeCount":98},[],{"trials":3419,"activeCount":98},[],{"trials":3421,"activeCount":98},[3422],{"nctId":3399,"briefTitle":3400,"status":132,"phases":3423,"primaryCompletion":3402,"completion":1190,"start":3403,"enrollment":3404,"conditions":3424,"interventions":3425},[88],[1193],[3390,3407],{"trials":3427,"activeCount":98},[],{"trials":3429,"activeCount":98},[],{"trials":3431,"activeCount":98},[],{"intervention":3433,"totalTrials":169,"cells":3434},"IL-2",{"EARLY_PHASE1":3435,"PHASE1":3437,"PHASE2":3439,"PHASE3":3448,"PHASE4":3450,"NA":3452},{"trials":3436,"activeCount":98},[],{"trials":3438,"activeCount":98},[],{"trials":3440,"activeCount":98},[3441],{"nctId":3442,"briefTitle":3443,"status":132,"phases":3444,"primaryCompletion":2401,"completion":2737,"start":1848,"enrollment":3445,"conditions":3446,"interventions":3447},"NCT04952155","Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome",[88],13,[15],[3433],{"trials":3449,"activeCount":98},[],{"trials":3451,"activeCount":98},[],{"trials":3453,"activeCount":98},[],{"intervention":3455,"totalTrials":169,"cells":3456},"Nitrofurazone Group 1",{"EARLY_PHASE1":3457,"PHASE1":3459,"PHASE2":3461,"PHASE3":3470,"PHASE4":3472,"NA":3474},{"trials":3458,"activeCount":98},[],{"trials":3460,"activeCount":98},[],{"trials":3462,"activeCount":98},[3463],{"nctId":3464,"briefTitle":3465,"status":132,"phases":3466,"primaryCompletion":2585,"completion":2737,"start":2119,"enrollment":2402,"conditions":3467,"interventions":3468},"NCT04950647","Efficacy and Safety of Nitrazine in the Treatment of ALS",[88],[15],[3455,3469],"Nitroketazine Group 2",{"trials":3471,"activeCount":98},[],{"trials":3473,"activeCount":98},[],{"trials":3475,"activeCount":98},[],{"intervention":3469,"totalTrials":169,"cells":3477},{"EARLY_PHASE1":3478,"PHASE1":3480,"PHASE2":3482,"PHASE3":3488,"PHASE4":3490,"NA":3492},{"trials":3479,"activeCount":98},[],{"trials":3481,"activeCount":98},[],{"trials":3483,"activeCount":98},[3484],{"nctId":3464,"briefTitle":3465,"status":132,"phases":3485,"primaryCompletion":2585,"completion":2737,"start":2119,"enrollment":2402,"conditions":3486,"interventions":3487},[88],[15],[3455,3469],{"trials":3489,"activeCount":98},[],{"trials":3491,"activeCount":98},[],{"trials":3493,"activeCount":98},[],{"intervention":3495,"totalTrials":169,"cells":3496},"Plant enteral-extended anti-reflux stents",{"EARLY_PHASE1":3497,"PHASE1":3499,"PHASE2":3501,"PHASE3":3513,"PHASE4":3515,"NA":3517},{"trials":3498,"activeCount":98},[],{"trials":3500,"activeCount":98},[],{"trials":3502,"activeCount":98},[3503],{"nctId":3504,"briefTitle":3505,"status":132,"phases":3506,"primaryCompletion":73,"completion":112,"start":3507,"enrollment":3508,"conditions":3509,"interventions":3511},"NCT05716594","Clinical Evaluation of Enteral-extended Anti-reflux Stents for Pancreatic Pseudocyst",[88],"2023-03-01",52,[3510],"Pancreatic Pseudocyst",[3495,3512],"Plant traditional stents",{"trials":3514,"activeCount":98},[],{"trials":3516,"activeCount":98},[],{"trials":3518,"activeCount":98},[],{"intervention":3512,"totalTrials":169,"cells":3520},{"EARLY_PHASE1":3521,"PHASE1":3523,"PHASE2":3525,"PHASE3":3531,"PHASE4":3533,"NA":3535},{"trials":3522,"activeCount":98},[],{"trials":3524,"activeCount":98},[],{"trials":3526,"activeCount":98},[3527],{"nctId":3504,"briefTitle":3505,"status":132,"phases":3528,"primaryCompletion":73,"completion":112,"start":3507,"enrollment":3508,"conditions":3529,"interventions":3530},[88],[3510],[3495,3512],{"trials":3532,"activeCount":98},[],{"trials":3534,"activeCount":98},[],{"trials":3536,"activeCount":98},[],{"intervention":3538,"totalTrials":169,"cells":3539},"autologous peripheral blood mesenchymal stem cell",{"EARLY_PHASE1":3540,"PHASE1":3542,"PHASE2":3553,"PHASE3":3555,"PHASE4":3557,"NA":3559},{"trials":3541,"activeCount":98},[],{"trials":3543,"activeCount":98},[3544],{"nctId":3545,"briefTitle":3546,"status":132,"phases":3547,"primaryCompletion":134,"completion":134,"start":2587,"enrollment":3548,"conditions":3549,"interventions":3551},"NCT04953572","Treatment of Cartilage Defects With Peripheral Blood Stem Cells",[87],252,[3550],"Cartilage Injury",[3538,3552],"Microfracture + collagen membrane",{"trials":3554,"activeCount":98},[],{"trials":3556,"activeCount":98},[],{"trials":3558,"activeCount":98},[],{"trials":3560,"activeCount":98},[],{"intervention":3552,"totalTrials":169,"cells":3562},{"EARLY_PHASE1":3563,"PHASE1":3565,"PHASE2":3571,"PHASE3":3573,"PHASE4":3575,"NA":3577},{"trials":3564,"activeCount":98},[],{"trials":3566,"activeCount":98},[3567],{"nctId":3545,"briefTitle":3546,"status":132,"phases":3568,"primaryCompletion":134,"completion":134,"start":2587,"enrollment":3548,"conditions":3569,"interventions":3570},[87],[3550],[3538,3552],{"trials":3572,"activeCount":98},[],{"trials":3574,"activeCount":98},[],{"trials":3576,"activeCount":98},[],{"trials":3578,"activeCount":98},[],{"intervention":3580,"totalTrials":169,"cells":3581},"Human Dental Pulp Stem Cells",{"EARLY_PHASE1":3582,"PHASE1":3584,"PHASE2":3596,"PHASE3":3598,"PHASE4":3600,"NA":3602},{"trials":3583,"activeCount":98},[],{"trials":3585,"activeCount":98},[3586],{"nctId":3587,"briefTitle":3588,"status":132,"phases":3589,"primaryCompletion":3590,"completion":3591,"start":3592,"enrollment":3593,"conditions":3594,"interventions":3595},"NCT04983225","The Safety and Tolerability of Initial Periodontal Therapy Combined With Human Dental Pulp Stem Cell Injection in the Treatment of Chronic Periodontitis",[87],"2024-07-31","2024-08-31","2021-07-31",36,[462],[3580],{"trials":3597,"activeCount":98},[],{"trials":3599,"activeCount":98},[],{"trials":3601,"activeCount":98},[],{"trials":3603,"activeCount":98},[],{"intervention":3605,"totalTrials":169,"cells":3606},"Apatinib Mesylate",{"EARLY_PHASE1":3607,"PHASE1":3609,"PHASE2":3622,"PHASE3":3624,"PHASE4":3626,"NA":3628},{"trials":3608,"activeCount":98},[],{"trials":3610,"activeCount":98},[3611],{"nctId":3612,"briefTitle":3613,"status":132,"phases":3614,"primaryCompletion":3615,"completion":3616,"start":3617,"enrollment":556,"conditions":3618,"interventions":3620},"NCT03050411","Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer",[87],"2019-06","2019-10","2016-05",[3619],"Nonsmall Cell Lung Cancer",[3605,3621],"EGFR-TKIs",{"trials":3623,"activeCount":98},[],{"trials":3625,"activeCount":98},[],{"trials":3627,"activeCount":98},[],{"trials":3629,"activeCount":98},[],{"intervention":3621,"totalTrials":169,"cells":3631},{"EARLY_PHASE1":3632,"PHASE1":3634,"PHASE2":3640,"PHASE3":3642,"PHASE4":3644,"NA":3646},{"trials":3633,"activeCount":98},[],{"trials":3635,"activeCount":98},[3636],{"nctId":3612,"briefTitle":3613,"status":132,"phases":3637,"primaryCompletion":3615,"completion":3616,"start":3617,"enrollment":556,"conditions":3638,"interventions":3639},[87],[3619],[3605,3621],{"trials":3641,"activeCount":98},[],{"trials":3643,"activeCount":98},[],{"trials":3645,"activeCount":98},[],{"trials":3647,"activeCount":98},[],{"intervention":3649,"totalTrials":169,"cells":3650},"ZVS101e",{"EARLY_PHASE1":3651,"PHASE1":3662,"PHASE2":3664,"PHASE3":3666,"PHASE4":3668,"NA":3670},{"trials":3652,"activeCount":98},[3653],{"nctId":3654,"briefTitle":3655,"status":132,"phases":3656,"primaryCompletion":3657,"completion":3657,"start":3658,"enrollment":1058,"conditions":3659,"interventions":3661},"NCT05714904","Safety and Tolerability of ZVS101e in Patients With Bietti 's Crystalline Dystrophy",[86],"2025-03-31","2022-09-23",[3660],"Bietti's Crystalline Dystrophy",[3649],{"trials":3663,"activeCount":98},[],{"trials":3665,"activeCount":98},[],{"trials":3667,"activeCount":98},[],{"trials":3669,"activeCount":98},[],{"trials":3671,"activeCount":98},[],{"intervention":3673,"totalTrials":169,"cells":3674},"ZVS203e",{"EARLY_PHASE1":3675,"PHASE1":3685,"PHASE2":3687,"PHASE3":3689,"PHASE4":3691,"NA":3693},{"trials":3676,"activeCount":98},[3677],{"nctId":3678,"briefTitle":3679,"status":132,"phases":3680,"primaryCompletion":240,"completion":240,"start":3681,"enrollment":654,"conditions":3682,"interventions":3684},"NCT05805007","Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa",[86],"2023-09-12",[3683],"Retinitis Pigmentosa",[3673],{"trials":3686,"activeCount":98},[],{"trials":3688,"activeCount":98},[],{"trials":3690,"activeCount":98},[],{"trials":3692,"activeCount":98},[],{"trials":3694,"activeCount":98},[],{"intervention":2726,"totalTrials":169,"cells":3696},{"EARLY_PHASE1":3697,"PHASE1":3703,"PHASE2":3705,"PHASE3":3707,"PHASE4":3709,"NA":3711},{"trials":3698,"activeCount":98},[3699],{"nctId":2719,"briefTitle":2720,"status":870,"phases":3700,"primaryCompletion":2722,"completion":2722,"start":2723,"enrollment":375,"conditions":3701,"interventions":3702},[86],[15],[2726,2714],{"trials":3704,"activeCount":98},[],{"trials":3706,"activeCount":98},[],{"trials":3708,"activeCount":98},[],{"trials":3710,"activeCount":98},[],{"trials":3712,"activeCount":98},[],{"intervention":3714,"totalTrials":126,"cells":3715},"Trastuzumab",{"EARLY_PHASE1":3716,"PHASE1":3718,"PHASE2":3720,"PHASE3":3722,"PHASE4":3724,"NA":3726},{"trials":3717,"activeCount":98},[],{"trials":3719,"activeCount":98},[],{"trials":3721,"activeCount":98},[],{"trials":3723,"activeCount":98},[],{"trials":3725,"activeCount":98},[],{"trials":3727,"activeCount":98},[3728,3738],{"nctId":3729,"briefTitle":3730,"status":132,"phases":3731,"primaryCompletion":2033,"completion":3732,"start":3733,"enrollment":556,"conditions":3734,"interventions":3737},"NCT04961307","Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab",[],"2021-12-30","2019-07-05",[3026,3735,3736,3714],"Antitumor Drugs","Breast Cancer",[3714],{"nctId":3739,"briefTitle":3740,"status":132,"phases":3741,"primaryCompletion":1988,"completion":3732,"start":3742,"enrollment":943,"conditions":3743,"interventions":3745},"NCT04962425","Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients",[],"2021-01-08",[3744,3735,3736],"Cardiac Toxicity",[3714],{"intervention":3747,"totalTrials":126,"cells":3748},"Anlotinib",{"EARLY_PHASE1":3749,"PHASE1":3751,"PHASE2":3753,"PHASE3":3764,"PHASE4":3766,"NA":3768},{"trials":3750,"activeCount":98},[],{"trials":3752,"activeCount":98},[],{"trials":3754,"activeCount":98},[3755],{"nctId":3756,"briefTitle":3757,"status":132,"phases":3758,"primaryCompletion":3759,"completion":3760,"start":3761,"enrollment":1124,"conditions":3762,"interventions":3763},"NCT04147728","Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC",[88],"2021-12-15","2022-12-15","2019-12-24",[1100],[3747],{"trials":3765,"activeCount":98},[],{"trials":3767,"activeCount":98},[],{"trials":3769,"activeCount":98},[3770],{"nctId":3771,"briefTitle":3772,"status":870,"phases":3773,"primaryCompletion":1988,"completion":1988,"start":3774,"enrollment":556,"conditions":3775,"interventions":3776},"NCT04912128","Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases in NSCLC",[],"2017-01-15",[1100],[3747],{"intervention":3778,"totalTrials":126,"cells":3779},"Recombinant Human Endostatin",{"EARLY_PHASE1":3780,"PHASE1":3782,"PHASE2":3784,"PHASE3":3786,"PHASE4":3799,"NA":3801},{"trials":3781,"activeCount":98},[],{"trials":3783,"activeCount":98},[],{"trials":3785,"activeCount":98},[],{"trials":3787,"activeCount":98},[3788],{"nctId":3789,"briefTitle":3790,"status":132,"phases":3791,"primaryCompletion":3792,"completion":3793,"start":3794,"enrollment":1934,"conditions":3795,"interventions":3797},"NCT02350361","Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.",[88,89],"2015-07","2016-03","2014-01",[3796],"Lung Cancer",[3798],"Recombinant human endostatin",{"trials":3800,"activeCount":98},[],{"trials":3802,"activeCount":98},[3803],{"nctId":3804,"briefTitle":3805,"status":132,"phases":3806,"primaryCompletion":3807,"completion":3808,"start":3809,"enrollment":556,"conditions":3810,"interventions":3811},"NCT05879796","Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer",[],"2024-05-16","2026-05-16","2023-05-16",[583],[3812,3813,3778],"cis-platinum","Envafolimab",{"intervention":3815,"totalTrials":169,"cells":3816},"Cladribine",{"EARLY_PHASE1":3817,"PHASE1":3819,"PHASE2":3821,"PHASE3":3823,"PHASE4":3825,"NA":3827},{"trials":3818,"activeCount":98},[],{"trials":3820,"activeCount":98},[],{"trials":3822,"activeCount":98},[],{"trials":3824,"activeCount":98},[],{"trials":3826,"activeCount":98},[],{"trials":3828,"activeCount":98},[3829],{"nctId":3830,"briefTitle":3831,"status":132,"phases":3832,"primaryCompletion":3378,"completion":3833,"start":729,"enrollment":1124,"conditions":3834,"interventions":3836},"NCT04679506","the Efficacy and Safety of CLAE in R\u002FR T-ALL\u002FLBL",[],"2023-12",[3835],"Precursor T-Cell Lymphoblastic Leukemia-Lymphoma",[3815],{"intervention":3838,"totalTrials":169,"cells":3839},"Ulinastatin",{"EARLY_PHASE1":3840,"PHASE1":3842,"PHASE2":3844,"PHASE3":3846,"PHASE4":3848,"NA":3850},{"trials":3841,"activeCount":98},[],{"trials":3843,"activeCount":98},[],{"trials":3845,"activeCount":98},[],{"trials":3847,"activeCount":98},[],{"trials":3849,"activeCount":98},[],{"trials":3851,"activeCount":98},[3852],{"nctId":3853,"briefTitle":3854,"status":870,"phases":3855,"primaryCompletion":3856,"completion":1989,"start":3857,"enrollment":3858,"conditions":3859,"interventions":3862},"NCT03089957","Prevention of Ulinastatin on Acute Respiratory Distress Syndrome (ARDS)",[91],"2020-12-17","2017-02-20",840,[3860,3861],"Acute Respiratory Distress Syndrome","Critical Illness",[3838],{"intervention":3864,"totalTrials":169,"cells":3865},"Spironolactone",{"EARLY_PHASE1":3866,"PHASE1":3868,"PHASE2":3870,"PHASE3":3872,"PHASE4":3874,"NA":3876},{"trials":3867,"activeCount":98},[],{"trials":3869,"activeCount":98},[],{"trials":3871,"activeCount":98},[],{"trials":3873,"activeCount":98},[],{"trials":3875,"activeCount":98},[],{"trials":3877,"activeCount":98},[3878],{"nctId":3879,"briefTitle":3880,"status":132,"phases":3881,"primaryCompletion":3882,"completion":729,"start":3883,"enrollment":3884,"conditions":3885,"interventions":3887},"NCT03626506","Spironolactone Versus Indapamide in Obese and Hypertensive Patients",[91],"2020-08","2019-02-13",400,[3886],"Hypertension",[3864,3888,3889],"Indapamide","Amlodipine",{"intervention":3888,"totalTrials":169,"cells":3891},{"EARLY_PHASE1":3892,"PHASE1":3894,"PHASE2":3896,"PHASE3":3898,"PHASE4":3900,"NA":3902},{"trials":3893,"activeCount":98},[],{"trials":3895,"activeCount":98},[],{"trials":3897,"activeCount":98},[],{"trials":3899,"activeCount":98},[],{"trials":3901,"activeCount":98},[],{"trials":3903,"activeCount":98},[3904],{"nctId":3879,"briefTitle":3880,"status":132,"phases":3905,"primaryCompletion":3882,"completion":729,"start":3883,"enrollment":3884,"conditions":3906,"interventions":3907},[91],[3886],[3864,3888,3889],{"intervention":3889,"totalTrials":169,"cells":3909},{"EARLY_PHASE1":3910,"PHASE1":3912,"PHASE2":3914,"PHASE3":3916,"PHASE4":3918,"NA":3920},{"trials":3911,"activeCount":98},[],{"trials":3913,"activeCount":98},[],{"trials":3915,"activeCount":98},[],{"trials":3917,"activeCount":98},[],{"trials":3919,"activeCount":98},[],{"trials":3921,"activeCount":98},[3922],{"nctId":3879,"briefTitle":3880,"status":132,"phases":3923,"primaryCompletion":3882,"completion":729,"start":3883,"enrollment":3884,"conditions":3924,"interventions":3925},[91],[3886],[3864,3888,3889],{"intervention":3927,"totalTrials":169,"cells":3928},"chlorhexidine acetate gargle",{"EARLY_PHASE1":3929,"PHASE1":3931,"PHASE2":3933,"PHASE3":3935,"PHASE4":3937,"NA":3939},{"trials":3930,"activeCount":98},[],{"trials":3932,"activeCount":98},[],{"trials":3934,"activeCount":98},[],{"trials":3936,"activeCount":98},[],{"trials":3938,"activeCount":98},[],{"trials":3940,"activeCount":98},[3941],{"nctId":3942,"briefTitle":3943,"status":132,"phases":3944,"primaryCompletion":3615,"completion":3945,"start":3946,"enrollment":3947,"conditions":3948,"interventions":3950},"NCT03492827","Evaluation of the Preventive Effect of Chlorhexidine Acetate Gargle for Upper Gastrointestinal Tract Infection After ESD",[91],"2019-09","2017-06-01",306,[3949,632],"Esophageal Cancer",[3927],{"intervention":3952,"totalTrials":169,"cells":3953},"Yangxue Qingnao Granules",{"EARLY_PHASE1":3954,"PHASE1":3956,"PHASE2":3958,"PHASE3":3960,"PHASE4":3962,"NA":3964},{"trials":3955,"activeCount":98},[],{"trials":3957,"activeCount":98},[],{"trials":3959,"activeCount":98},[],{"trials":3961,"activeCount":98},[],{"trials":3963,"activeCount":98},[],{"trials":3965,"activeCount":98},[3966],{"nctId":3967,"briefTitle":3968,"status":132,"phases":3969,"primaryCompletion":3970,"completion":3971,"start":1375,"enrollment":1934,"conditions":3972,"interventions":3974},"NCT06344312","Effectiveness of Yangxue Qingnao Granules in Preventing Post Thrombolytic Hemorrhage Transformation in Patients With Acute Cerebral Infarction",[91],"2025-01-01","2025-06-01",[3973],"Stroke, Acute Ischemic",[3952],{"intervention":3976,"totalTrials":169,"cells":3977},"Sodium hyaluronate eye drops",{"EARLY_PHASE1":3978,"PHASE1":3980,"PHASE2":3982,"PHASE3":3984,"PHASE4":3986,"NA":3988},{"trials":3979,"activeCount":98},[],{"trials":3981,"activeCount":98},[],{"trials":3983,"activeCount":98},[],{"trials":3985,"activeCount":98},[],{"trials":3987,"activeCount":98},[],{"trials":3989,"activeCount":98},[3990],{"nctId":3991,"briefTitle":3992,"status":870,"phases":3993,"primaryCompletion":3994,"completion":2146,"start":3995,"enrollment":375,"conditions":3996,"interventions":3997},"NCT04668131","Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease",[91],"2022-03-30","2020-09-22",[25],[3976],{"intervention":3999,"totalTrials":169,"cells":4000},"Metformin intervention for 12 weeks",{"EARLY_PHASE1":4001,"PHASE1":4003,"PHASE2":4005,"PHASE3":4007,"PHASE4":4009,"NA":4011},{"trials":4002,"activeCount":98},[],{"trials":4004,"activeCount":98},[],{"trials":4006,"activeCount":98},[],{"trials":4008,"activeCount":98},[],{"trials":4010,"activeCount":98},[],{"trials":4012,"activeCount":98},[4013],{"nctId":4014,"briefTitle":4015,"status":870,"phases":4016,"primaryCompletion":2653,"completion":4017,"start":2738,"enrollment":4018,"conditions":4019,"interventions":4021},"NCT05802212","Effect of Metformin on Patients With Polycystic Ovary Syndrome",[91],"2023-05-01",77,[4020],"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries",[3999],{"intervention":4023,"totalTrials":169,"cells":4024},"Tylenol",{"EARLY_PHASE1":4025,"PHASE1":4027,"PHASE2":4029,"PHASE3":4031,"PHASE4":4033,"NA":4035},{"trials":4026,"activeCount":98},[],{"trials":4028,"activeCount":98},[],{"trials":4030,"activeCount":98},[],{"trials":4032,"activeCount":98},[],{"trials":4034,"activeCount":98},[],{"trials":4036,"activeCount":98},[4037],{"nctId":4038,"briefTitle":4039,"status":870,"phases":4040,"primaryCompletion":4041,"completion":4042,"start":4043,"enrollment":4044,"conditions":4045,"interventions":4048},"NCT04042948","Clinical Effect of Preventive Use of Tylenol on Fever After Removal of Drainage Tube in Lumbar Fusion Surgery",[91],"2019-11-30","2019-12-30","2019-06-24",183,[28,4046,4047],"Lumbar Disc Herniation","Lumbar Radiculopathy",[4023],{"intervention":4050,"totalTrials":169,"cells":4051},"Fast Inpatient Rehabilitation",{"EARLY_PHASE1":4052,"PHASE1":4054,"PHASE2":4056,"PHASE3":4058,"PHASE4":4060,"NA":4062},{"trials":4053,"activeCount":98},[],{"trials":4055,"activeCount":98},[],{"trials":4057,"activeCount":98},[],{"trials":4059,"activeCount":98},[],{"trials":4061,"activeCount":98},[],{"trials":4063,"activeCount":98},[4064],{"nctId":4065,"briefTitle":4066,"status":132,"phases":4067,"primaryCompletion":4068,"completion":4069,"start":4070,"enrollment":1934,"conditions":4071,"interventions":4074},"NCT04458480","Effect of Fast Inpatient Rehabilitation After TKA",[],"2020-09-06","2021-03-06","2019-09-07",[4072,4073],"Total Knee Arthroplasty","Rehabilitation",[4050],{"intervention":4076,"totalTrials":169,"cells":4077},"YJ001",{"EARLY_PHASE1":4078,"PHASE1":4080,"PHASE2":4082,"PHASE3":4084,"PHASE4":4086,"NA":4088},{"trials":4079,"activeCount":98},[],{"trials":4081,"activeCount":98},[],{"trials":4083,"activeCount":98},[],{"trials":4085,"activeCount":98},[],{"trials":4087,"activeCount":98},[],{"trials":4089,"activeCount":98},[4090],{"nctId":4091,"briefTitle":4092,"status":132,"phases":4093,"primaryCompletion":4094,"completion":711,"start":1989,"enrollment":4095,"conditions":4096,"interventions":4098},"NCT04953221","The Effect of YJ001 on Diabetic Peripheral Neuropathic Pain.",[],"2022-07-01",225,[4097],"Diabetic Peripheral Neuropathic Pain",[4076],{"intervention":4100,"totalTrials":169,"cells":4101},"Clinical probes",{"EARLY_PHASE1":4102,"PHASE1":4104,"PHASE2":4106,"PHASE3":4108,"PHASE4":4110,"NA":4112},{"trials":4103,"activeCount":98},[],{"trials":4105,"activeCount":98},[],{"trials":4107,"activeCount":98},[],{"trials":4109,"activeCount":98},[],{"trials":4111,"activeCount":98},[],{"trials":4113,"activeCount":98},[4114],{"nctId":4115,"briefTitle":4116,"status":132,"phases":4117,"primaryCompletion":4118,"completion":4119,"start":4120,"enrollment":4121,"conditions":4122,"interventions":4124},"NCT05893849","Pharmacokinetics of Clinical Probes and Characteristics of Endogenous Biomarker in Chinese Older Adults",[],"2024-03","2024-04","2023-03-28",624,[4123],"Aging",[4100],{"intervention":4126,"totalTrials":169,"cells":4127},"Tobramycin and Dexamethasone Ophthalmic Ointment",{"EARLY_PHASE1":4128,"PHASE1":4130,"PHASE2":4132,"PHASE3":4134,"PHASE4":4136,"NA":4138},{"trials":4129,"activeCount":98},[],{"trials":4131,"activeCount":98},[],{"trials":4133,"activeCount":98},[],{"trials":4135,"activeCount":98},[],{"trials":4137,"activeCount":98},[],{"trials":4139,"activeCount":98},[4140],{"nctId":4141,"briefTitle":4142,"status":870,"phases":4143,"primaryCompletion":4144,"completion":4145,"start":4146,"enrollment":375,"conditions":4147,"interventions":4149},"NCT02958514","Efficacy Comparison of Two Kinds of Treatment in Treating Dry Eye Caused by Meibomian Gland Dysfunction",[91],"2017-02","2017-03","2016-11",[4148],"Dry Eye Syndrome",[4126],{"intervention":4151,"totalTrials":169,"cells":4152},"Vitamin D2",{"EARLY_PHASE1":4153,"PHASE1":4155,"PHASE2":4157,"PHASE3":4159,"PHASE4":4161,"NA":4163},{"trials":4154,"activeCount":98},[],{"trials":4156,"activeCount":98},[],{"trials":4158,"activeCount":98},[],{"trials":4160,"activeCount":98},[],{"trials":4162,"activeCount":98},[],{"trials":4164,"activeCount":98},[4165],{"nctId":4166,"briefTitle":4167,"status":132,"phases":4168,"primaryCompletion":4169,"completion":4170,"start":4171,"enrollment":4172,"conditions":4173,"interventions":4175},"NCT05673980","Oral Vitamin D2 for Prevention of COVID-19",[91],"2023-01-19","2023-02-20","2022-12-18",218,[4174],"Healthy Volunteers",[4151],{"intervention":4177,"totalTrials":169,"cells":4178},"Respiratory rehabilitation",{"EARLY_PHASE1":4179,"PHASE1":4181,"PHASE2":4183,"PHASE3":4185,"PHASE4":4187,"NA":4189},{"trials":4180,"activeCount":98},[],{"trials":4182,"activeCount":98},[],{"trials":4184,"activeCount":98},[],{"trials":4186,"activeCount":98},[],{"trials":4188,"activeCount":98},[],{"trials":4190,"activeCount":98},[4191],{"nctId":4192,"briefTitle":4193,"status":132,"phases":4194,"primaryCompletion":4195,"completion":4196,"start":4197,"enrollment":1307,"conditions":4198,"interventions":4203},"NCT04382534","A Cross-sectional and Cohort Study of COVID-19 Patients With Post - Discharge Dysfunction",[],"2020-09-30","2020-12-31","2020-03-10",[4199,4200,4201,4202],"Covid19","Respiratory Rehabilitation","Cross-sectional Study","Cohort Study",[4177],{"intervention":4205,"totalTrials":169,"cells":4206},"the timing of embryo transfer in freeze-all cycles",{"EARLY_PHASE1":4207,"PHASE1":4209,"PHASE2":4211,"PHASE3":4213,"PHASE4":4215,"NA":4217},{"trials":4208,"activeCount":98},[],{"trials":4210,"activeCount":98},[],{"trials":4212,"activeCount":98},[],{"trials":4214,"activeCount":98},[],{"trials":4216,"activeCount":98},[],{"trials":4218,"activeCount":98},[4219],{"nctId":4220,"briefTitle":4221,"status":870,"phases":4222,"primaryCompletion":4223,"completion":4224,"start":4225,"enrollment":4226,"conditions":4227,"interventions":4228},"NCT05483270","Immediate Versus Postponed Freeze-all Embryo Transfer in Hyperresponders",[91],"2024-10-08","2024-11-24","2022-08-30",845,[1785],[4205],{"intervention":141,"totalTrials":169,"cells":4230},{"EARLY_PHASE1":4231,"PHASE1":4233,"PHASE2":4235,"PHASE3":4237,"PHASE4":4239,"NA":4241},{"trials":4232,"activeCount":98},[],{"trials":4234,"activeCount":98},[],{"trials":4236,"activeCount":98},[],{"trials":4238,"activeCount":98},[],{"trials":4240,"activeCount":98},[],{"trials":4242,"activeCount":98},[4243],{"nctId":130,"briefTitle":131,"status":132,"phases":4244,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":4245,"interventions":4246},[91],[139],[54,141],{"intervention":4248,"totalTrials":169,"cells":4249},"Nitrate ketone oxazine",{"EARLY_PHASE1":4250,"PHASE1":4252,"PHASE2":4254,"PHASE3":4256,"PHASE4":4258,"NA":4260},{"trials":4251,"activeCount":98},[],{"trials":4253,"activeCount":98},[],{"trials":4255,"activeCount":98},[],{"trials":4257,"activeCount":98},[],{"trials":4259,"activeCount":98},[],{"trials":4261,"activeCount":98},[4262],{"nctId":4263,"briefTitle":4264,"status":132,"phases":4265,"primaryCompletion":4266,"completion":2033,"start":4267,"enrollment":713,"conditions":4268,"interventions":4269},"NCT04951440","Study on the Effectiveness and Safety of Nitrone for Injection in Patients With Acute Ischemic Stroke",[91],"2020-12-01","2018-06-01",[2037],[4248],{"intervention":4271,"totalTrials":169,"cells":4272},"Camrelizumab",{"EARLY_PHASE1":4273,"PHASE1":4275,"PHASE2":4277,"PHASE3":4279,"PHASE4":4281,"NA":4283},{"trials":4274,"activeCount":98},[],{"trials":4276,"activeCount":98},[],{"trials":4278,"activeCount":98},[],{"trials":4280,"activeCount":98},[],{"trials":4282,"activeCount":98},[],{"trials":4284,"activeCount":98},[4285],{"nctId":4286,"briefTitle":4287,"status":132,"phases":4288,"primaryCompletion":3129,"completion":4289,"start":4290,"enrollment":375,"conditions":4291,"interventions":4293},"NCT05600998","A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma",[91],"2024-02-28","2022-10-30",[4292],"Ovarian Clear Cell Carcinoma",[4271],{"intervention":4295,"totalTrials":169,"cells":4296},"Developmental assessment",{"EARLY_PHASE1":4297,"PHASE1":4299,"PHASE2":4301,"PHASE3":4303,"PHASE4":4305,"NA":4307},{"trials":4298,"activeCount":98},[],{"trials":4300,"activeCount":98},[],{"trials":4302,"activeCount":98},[],{"trials":4304,"activeCount":98},[],{"trials":4306,"activeCount":98},[],{"trials":4308,"activeCount":98},[4309],{"nctId":4310,"briefTitle":4311,"status":132,"phases":4312,"primaryCompletion":4313,"completion":4313,"start":4266,"enrollment":4314,"conditions":4315,"interventions":4317},"NCT04817878","Cohort Construction for Preterm Infants With Growth Retardation and Its Influencing Factors",[],"2023-11-30",2400,[4316],"Problem With Growth of an Infant",[4295],{"intervention":4319,"totalTrials":169,"cells":4320},"Ropivacaine",{"EARLY_PHASE1":4321,"PHASE1":4323,"PHASE2":4325,"PHASE3":4327,"PHASE4":4329,"NA":4331},{"trials":4322,"activeCount":98},[],{"trials":4324,"activeCount":98},[],{"trials":4326,"activeCount":98},[],{"trials":4328,"activeCount":98},[],{"trials":4330,"activeCount":98},[],{"trials":4332,"activeCount":98},[4333],{"nctId":4334,"briefTitle":4335,"status":870,"phases":4336,"primaryCompletion":4337,"completion":4338,"start":4339,"enrollment":330,"conditions":4340,"interventions":4344},"NCT05320718","Analgesia in Minimally Invasive Direct Coronary Artery Bypass Grafting: Programmed Intermittent Bolus Infusions of Erector Spinae Plane Block Versus Paravertebral Block",[91],"2023-04-30","2023-12-30","2022-04-15",[4341,4342,4343],"Regional Anesthesia","Anesthesia, Local","Surgery",[4319],{"intervention":4346,"totalTrials":169,"cells":4347},"Neupro",{"EARLY_PHASE1":4348,"PHASE1":4350,"PHASE2":4352,"PHASE3":4354,"PHASE4":4356,"NA":4358},{"trials":4349,"activeCount":98},[],{"trials":4351,"activeCount":98},[],{"trials":4353,"activeCount":98},[],{"trials":4355,"activeCount":98},[],{"trials":4357,"activeCount":98},[],{"trials":4359,"activeCount":98},[4360],{"nctId":4361,"briefTitle":4362,"status":132,"phases":4363,"primaryCompletion":2401,"completion":4364,"start":1989,"enrollment":4365,"conditions":4366,"interventions":4367},"NCT04957420","The Practical Effect of Neupro",[],"2022-04-30",3000,[2960],[4346],{"intervention":4369,"totalTrials":169,"cells":4370},"sodium bicarbonate",{"EARLY_PHASE1":4371,"PHASE1":4373,"PHASE2":4375,"PHASE3":4377,"PHASE4":4379,"NA":4381},{"trials":4372,"activeCount":98},[],{"trials":4374,"activeCount":98},[],{"trials":4376,"activeCount":98},[],{"trials":4378,"activeCount":98},[],{"trials":4380,"activeCount":98},[],{"trials":4382,"activeCount":98},[4383],{"nctId":4384,"briefTitle":4385,"status":870,"phases":4386,"primaryCompletion":4387,"completion":4388,"start":4389,"enrollment":4390,"conditions":4391,"interventions":4393},"NCT04953013","Risk Potential for Organ Dysfunction Associated With Sodium Bicarbonate Therapy (SBT) in Critically Ill Patients",[],"2020-02-01","2020-09-01","2019-08-01",664,[4392],"Metabolic Acidosis; Critically Ill Patients; Organ Dysfunction",[4369],{"intervention":4395,"totalTrials":169,"cells":4396},"Rosuvastatin",{"EARLY_PHASE1":4397,"PHASE1":4399,"PHASE2":4401,"PHASE3":4403,"PHASE4":4405,"NA":4407},{"trials":4398,"activeCount":98},[],{"trials":4400,"activeCount":98},[],{"trials":4402,"activeCount":98},[],{"trials":4404,"activeCount":98},[],{"trials":4406,"activeCount":98},[],{"trials":4408,"activeCount":98},[4409],{"nctId":4410,"briefTitle":4411,"status":132,"phases":4412,"primaryCompletion":4413,"completion":4414,"start":4415,"enrollment":1376,"conditions":4416,"interventions":4418},"NCT01653119","Peking and Rotterdam on Mission to Reduce Coronary Artery Disease",[91],"2015-06","2015-12","2012-04",[4417,1525],"Acute Coronary Syndrome",[4395],{"intervention":3812,"totalTrials":169,"cells":4420},{"EARLY_PHASE1":4421,"PHASE1":4423,"PHASE2":4425,"PHASE3":4427,"PHASE4":4429,"NA":4431},{"trials":4422,"activeCount":98},[],{"trials":4424,"activeCount":98},[],{"trials":4426,"activeCount":98},[],{"trials":4428,"activeCount":98},[],{"trials":4430,"activeCount":98},[],{"trials":4432,"activeCount":98},[4433],{"nctId":3804,"briefTitle":3805,"status":132,"phases":4434,"primaryCompletion":3807,"completion":3808,"start":3809,"enrollment":556,"conditions":4435,"interventions":4436},[],[583],[3812,3813,3778],{"intervention":3813,"totalTrials":169,"cells":4438},{"EARLY_PHASE1":4439,"PHASE1":4441,"PHASE2":4443,"PHASE3":4445,"PHASE4":4447,"NA":4449},{"trials":4440,"activeCount":98},[],{"trials":4442,"activeCount":98},[],{"trials":4444,"activeCount":98},[],{"trials":4446,"activeCount":98},[],{"trials":4448,"activeCount":98},[],{"trials":4450,"activeCount":98},[4451],{"nctId":3804,"briefTitle":3805,"status":132,"phases":4452,"primaryCompletion":3807,"completion":3808,"start":3809,"enrollment":556,"conditions":4453,"interventions":4454},[],[583],[3812,3813,3778],{"intervention":4456,"totalTrials":169,"cells":4457},"Intercostal Nerve Block with PCIA",{"EARLY_PHASE1":4458,"PHASE1":4460,"PHASE2":4462,"PHASE3":4464,"PHASE4":4466,"NA":4468},{"trials":4459,"activeCount":98},[],{"trials":4461,"activeCount":98},[],{"trials":4463,"activeCount":98},[],{"trials":4465,"activeCount":98},[],{"trials":4467,"activeCount":98},[],{"trials":4469,"activeCount":98},[4470],{"nctId":4471,"briefTitle":4472,"status":870,"phases":4473,"primaryCompletion":4474,"completion":4474,"start":4475,"enrollment":1149,"conditions":4476,"interventions":4478},"NCT03682354","ESPB Versus INB With PCIA in Video-assisted Thoracic Surgery",[91],"2019-03-15","2018-09-27",[4477],"Lung Diseases",[4456,4479],"Erector Spinae Plane Block",{"intervention":4479,"totalTrials":169,"cells":4481},{"EARLY_PHASE1":4482,"PHASE1":4484,"PHASE2":4486,"PHASE3":4488,"PHASE4":4490,"NA":4492},{"trials":4483,"activeCount":98},[],{"trials":4485,"activeCount":98},[],{"trials":4487,"activeCount":98},[],{"trials":4489,"activeCount":98},[],{"trials":4491,"activeCount":98},[],{"trials":4493,"activeCount":98},[4494],{"nctId":4471,"briefTitle":4472,"status":870,"phases":4495,"primaryCompletion":4474,"completion":4474,"start":4475,"enrollment":1149,"conditions":4496,"interventions":4497},[91],[4477],[4456,4479],{"intervention":4499,"totalTrials":169,"cells":4500},"Drug: Cisplatin; nab-paclitaxel",{"EARLY_PHASE1":4501,"PHASE1":4503,"PHASE2":4505,"PHASE3":4507,"PHASE4":4509,"NA":4511},{"trials":4502,"activeCount":98},[],{"trials":4504,"activeCount":98},[],{"trials":4506,"activeCount":98},[],{"trials":4508,"activeCount":98},[],{"trials":4510,"activeCount":98},[],{"trials":4512,"activeCount":98},[4513],{"nctId":4514,"briefTitle":4515,"status":132,"phases":4516,"primaryCompletion":4517,"completion":4518,"start":4519,"enrollment":4520,"conditions":4521,"interventions":4522},"NCT04017377","VMAT Concurrent Cisplatin Plus Nab-paclitaxel for Local Advanced Cervical Cancer",[91],"2020-06-15","2020-07-15","2019-09-01",15,[583],[4499],{"intervention":4524,"totalTrials":169,"cells":4525},"Xinglouchengqi decoction",{"EARLY_PHASE1":4526,"PHASE1":4528,"PHASE2":4530,"PHASE3":4532,"PHASE4":4534,"NA":4536},{"trials":4527,"activeCount":98},[],{"trials":4529,"activeCount":98},[],{"trials":4531,"activeCount":98},[],{"trials":4533,"activeCount":98},[],{"trials":4535,"activeCount":98},[],{"trials":4537,"activeCount":98},[4538],{"nctId":4539,"briefTitle":4540,"status":132,"phases":4541,"primaryCompletion":4542,"completion":2077,"start":2120,"enrollment":556,"conditions":4543,"interventions":4544},"NCT04970797","Mechanism of Xinglouchengqi Decoction in Improving Nerve Injury in the Acute Stage of Stroke by EEG and Metabolomics",[],"2022-05-01",[33],[4524],{"intervention":4546,"totalTrials":169,"cells":4547},"Antitumor drugs",{"EARLY_PHASE1":4548,"PHASE1":4550,"PHASE2":4552,"PHASE3":4554,"PHASE4":4556,"NA":4558},{"trials":4549,"activeCount":98},[],{"trials":4551,"activeCount":98},[],{"trials":4553,"activeCount":98},[],{"trials":4555,"activeCount":98},[],{"trials":4557,"activeCount":98},[],{"trials":4559,"activeCount":98},[4560],{"nctId":4561,"briefTitle":4562,"status":132,"phases":4563,"primaryCompletion":2654,"completion":114,"start":4094,"enrollment":1124,"conditions":4564,"interventions":4565},"NCT05728788","Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy",[],[715],[4546],{"intervention":4567,"totalTrials":169,"cells":4568},"Types and exposure of different air pollutants",{"EARLY_PHASE1":4569,"PHASE1":4571,"PHASE2":4573,"PHASE3":4575,"PHASE4":4577,"NA":4579},{"trials":4570,"activeCount":98},[],{"trials":4572,"activeCount":98},[],{"trials":4574,"activeCount":98},[],{"trials":4576,"activeCount":98},[],{"trials":4578,"activeCount":98},[],{"trials":4580,"activeCount":98},[4581],{"nctId":4582,"briefTitle":4583,"status":870,"phases":4584,"primaryCompletion":4585,"completion":4586,"start":4587,"enrollment":241,"conditions":4588,"interventions":4590},"NCT04960410","Real Time Early Warning Model and Mobile Medical Assistant System for the Impact of Air Pollution on AECOPD Disease",[],"2017-04-23","2018-12-30","2017-01-01",[4589],"COPD",[4567],{"intervention":4592,"totalTrials":169,"cells":4593},"Guided cartilage regeneration membrane",{"EARLY_PHASE1":4594,"PHASE1":4596,"PHASE2":4598,"PHASE3":4600,"PHASE4":4602,"NA":4604},{"trials":4595,"activeCount":98},[],{"trials":4597,"activeCount":98},[],{"trials":4599,"activeCount":98},[],{"trials":4601,"activeCount":98},[],{"trials":4603,"activeCount":98},[],{"trials":4605,"activeCount":98},[4606],{"nctId":4607,"briefTitle":4608,"status":132,"phases":4609,"primaryCompletion":4610,"completion":4611,"start":4612,"enrollment":2402,"conditions":4613,"interventions":4616},"NCT04463238","Guided Cartilage Regeneration Membrane",[91],"2022-08-03","2023-08-03","2020-08-03",[4614,4615],"Articular Cartilage Injury","Knee Ligament Injury",[4592],{"intervention":4618,"totalTrials":169,"cells":4619},"Yangxue Qingnao pill",{"EARLY_PHASE1":4620,"PHASE1":4622,"PHASE2":4624,"PHASE3":4626,"PHASE4":4628,"NA":4630},{"trials":4621,"activeCount":98},[],{"trials":4623,"activeCount":98},[],{"trials":4625,"activeCount":98},[],{"trials":4627,"activeCount":98},[],{"trials":4629,"activeCount":98},[],{"trials":4631,"activeCount":98},[4632],{"nctId":4633,"briefTitle":4634,"status":870,"phases":4635,"primaryCompletion":4636,"completion":4637,"start":4638,"enrollment":1934,"conditions":4639,"interventions":4641},"NCT04958512","Treatment of Mild Vascular Cognitive Impairment With Yangxue Qingnao Pill",[91],"2018-01-31","2018-03-31","2017-08-30",[4640],"Cerebrovascular Diseases",[4618,4642],"Hydergotoxine mesylate",{"intervention":4642,"totalTrials":169,"cells":4644},{"EARLY_PHASE1":4645,"PHASE1":4647,"PHASE2":4649,"PHASE3":4651,"PHASE4":4653,"NA":4655},{"trials":4646,"activeCount":98},[],{"trials":4648,"activeCount":98},[],{"trials":4650,"activeCount":98},[],{"trials":4652,"activeCount":98},[],{"trials":4654,"activeCount":98},[],{"trials":4656,"activeCount":98},[4657],{"nctId":4633,"briefTitle":4634,"status":870,"phases":4658,"primaryCompletion":4636,"completion":4637,"start":4638,"enrollment":1934,"conditions":4659,"interventions":4660},[91],[4640],[4618,4642],{"intervention":4662,"totalTrials":169,"cells":4663},"Anti-VEGF",{"EARLY_PHASE1":4664,"PHASE1":4666,"PHASE2":4668,"PHASE3":4670,"PHASE4":4672,"NA":4674},{"trials":4665,"activeCount":98},[],{"trials":4667,"activeCount":98},[],{"trials":4669,"activeCount":98},[],{"trials":4671,"activeCount":98},[],{"trials":4673,"activeCount":98},[],{"trials":4675,"activeCount":98},[4676],{"nctId":4677,"briefTitle":4678,"status":132,"phases":4679,"primaryCompletion":2033,"completion":3732,"start":3733,"enrollment":556,"conditions":4680,"interventions":4683},"NCT04962438","Effects of Anti-VEGF Targeted Drugs on Patients' Blood Pressure and Endothelial Function",[],[3744,4681,4682],"VEGF","Endothelial Dysfunction",[4662],{"intervention":4685,"totalTrials":169,"cells":4686},"Endostar",{"EARLY_PHASE1":4687,"PHASE1":4689,"PHASE2":4691,"PHASE3":4693,"PHASE4":4695,"NA":4697},{"trials":4688,"activeCount":98},[],{"trials":4690,"activeCount":98},[],{"trials":4692,"activeCount":98},[],{"trials":4694,"activeCount":98},[],{"trials":4696,"activeCount":98},[],{"trials":4698,"activeCount":98},[4699],{"nctId":4700,"briefTitle":4701,"status":132,"phases":4702,"primaryCompletion":4703,"completion":4704,"start":1990,"enrollment":1934,"conditions":4705,"interventions":4707},"NCT04274270","SBRT With S1 Combined With Endostar in the Treatment of Lung Cancer",[91],"2022-01-30","2023-01-30",[4706],"Radiotherapy Side Effect",[4685],{"intervention":4709,"totalTrials":169,"cells":4710},"Raise serum brain granules",{"EARLY_PHASE1":4711,"PHASE1":4713,"PHASE2":4715,"PHASE3":4717,"PHASE4":4719,"NA":4721},{"trials":4712,"activeCount":98},[],{"trials":4714,"activeCount":98},[],{"trials":4716,"activeCount":98},[],{"trials":4718,"activeCount":98},[],{"trials":4720,"activeCount":98},[],{"trials":4722,"activeCount":98},[4723],{"nctId":4724,"briefTitle":4725,"status":870,"phases":4726,"primaryCompletion":4388,"completion":4727,"start":2121,"enrollment":2402,"conditions":4728,"interventions":4730},"NCT04949906","Study on Yangxue Nao Granules Reducing the Risk of Stroke",[],"2020-11-01",[4729],"Cerebral Infarction",[4709,4731],"No nourishing serum brain granules are used",{"intervention":4731,"totalTrials":169,"cells":4733},{"EARLY_PHASE1":4734,"PHASE1":4736,"PHASE2":4738,"PHASE3":4740,"PHASE4":4742,"NA":4744},{"trials":4735,"activeCount":98},[],{"trials":4737,"activeCount":98},[],{"trials":4739,"activeCount":98},[],{"trials":4741,"activeCount":98},[],{"trials":4743,"activeCount":98},[],{"trials":4745,"activeCount":98},[4746],{"nctId":4724,"briefTitle":4725,"status":870,"phases":4747,"primaryCompletion":4388,"completion":4727,"start":2121,"enrollment":2402,"conditions":4748,"interventions":4749},[],[4729],[4709,4731],{"intervention":4751,"totalTrials":169,"cells":4752},"Single-nucleotide Polymorphism of genes related with Dyslipidemia",{"EARLY_PHASE1":4753,"PHASE1":4755,"PHASE2":4757,"PHASE3":4759,"PHASE4":4761,"NA":4763},{"trials":4754,"activeCount":98},[],{"trials":4756,"activeCount":98},[],{"trials":4758,"activeCount":98},[],{"trials":4760,"activeCount":98},[],{"trials":4762,"activeCount":98},[],{"trials":4764,"activeCount":98},[4765],{"nctId":4766,"briefTitle":4767,"status":870,"phases":4768,"primaryCompletion":4769,"completion":4769,"start":4770,"enrollment":4771,"conditions":4772,"interventions":4774},"NCT04950699","Peking University & University of Michigan Study of MI and Atherosclerosis",[],"2016-12-31","2012-01-01",4700,[4773],"Coronary Heart Disease",[4751],{"intervention":4776,"totalTrials":169,"cells":4777},"Dexamethasone",{"EARLY_PHASE1":4778,"PHASE1":4780,"PHASE2":4782,"PHASE3":4784,"PHASE4":4786,"NA":4788},{"trials":4779,"activeCount":98},[],{"trials":4781,"activeCount":98},[],{"trials":4783,"activeCount":98},[],{"trials":4785,"activeCount":98},[],{"trials":4787,"activeCount":98},[],{"trials":4789,"activeCount":98},[4790],{"nctId":4791,"briefTitle":4792,"status":132,"phases":4793,"primaryCompletion":4794,"completion":112,"start":4795,"enrollment":2469,"conditions":4796,"interventions":4798},"NCT06350565","A Clinical Pharmacological Study of Dose Halving of Dexamethasone in Pregnant Women With Preterm Labour With Preterm Birth at Greater Than or Equal to 34 Gestational Weeks (34GW+)",[91],"2025-04-30","2024-04-30",[4797],"Respiratory Distress Syndrome of Newborn",[4776],{"intervention":4800,"totalTrials":169,"cells":4801},"moxifloxacin",{"EARLY_PHASE1":4802,"PHASE1":4804,"PHASE2":4806,"PHASE3":4808,"PHASE4":4810,"NA":4812},{"trials":4803,"activeCount":98},[],{"trials":4805,"activeCount":98},[],{"trials":4807,"activeCount":98},[],{"trials":4809,"activeCount":98},[],{"trials":4811,"activeCount":98},[],{"trials":4813,"activeCount":98},[4814],{"nctId":4815,"briefTitle":4816,"status":132,"phases":4817,"primaryCompletion":4818,"completion":4819,"start":4820,"enrollment":3593,"conditions":4821,"interventions":4823},"NCT01653990","Moxifloxacin_QT Study in Chinese Healthy Volunteer",[91],"2012-09","2012-10","2012-07",[4822],"QT Interval Prolongation",[4800,4824],"moxifloxacin-placebo",{"intervention":4824,"totalTrials":169,"cells":4826},{"EARLY_PHASE1":4827,"PHASE1":4829,"PHASE2":4831,"PHASE3":4833,"PHASE4":4835,"NA":4837},{"trials":4828,"activeCount":98},[],{"trials":4830,"activeCount":98},[],{"trials":4832,"activeCount":98},[],{"trials":4834,"activeCount":98},[],{"trials":4836,"activeCount":98},[],{"trials":4838,"activeCount":98},[4839],{"nctId":4815,"briefTitle":4816,"status":132,"phases":4840,"primaryCompletion":4818,"completion":4819,"start":4820,"enrollment":3593,"conditions":4841,"interventions":4842},[91],[4822],[4800,4824],{"intervention":4844,"totalTrials":169,"cells":4845},"PD-1 blocking antibody",{"EARLY_PHASE1":4846,"PHASE1":4848,"PHASE2":4850,"PHASE3":4852,"PHASE4":4854,"NA":4856},{"trials":4847,"activeCount":98},[],{"trials":4849,"activeCount":98},[],{"trials":4851,"activeCount":98},[],{"trials":4853,"activeCount":98},[],{"trials":4855,"activeCount":98},[],{"trials":4857,"activeCount":98},[4858],{"nctId":4859,"briefTitle":4860,"status":870,"phases":4861,"primaryCompletion":4862,"completion":38,"start":4266,"enrollment":4863,"conditions":4864,"interventions":4867},"NCT06195254","Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer",[],"2023-05-21",19,[3178,4865,4866],"PD-1 Inhibitors","Pancreatic Cancer",[4844],{"intervention":4869,"totalTrials":169,"cells":4870},"etomidate",{"EARLY_PHASE1":4871,"PHASE1":4873,"PHASE2":4875,"PHASE3":4877,"PHASE4":4879,"NA":4881},{"trials":4872,"activeCount":98},[],{"trials":4874,"activeCount":98},[],{"trials":4876,"activeCount":98},[],{"trials":4878,"activeCount":98},[],{"trials":4880,"activeCount":98},[],{"trials":4882,"activeCount":98},[4883],{"nctId":4884,"briefTitle":4885,"status":132,"phases":4886,"primaryCompletion":3129,"completion":4338,"start":4887,"enrollment":713,"conditions":4888,"interventions":4891},"NCT05520645","Etomidate Induction in Hysteroscopic Surgery",[91],"2022-08-25",[4889,4890],"Etomidate Induced Dose","Hysteroscopic Surgery",[4869,4892],"propofol",{"intervention":4892,"totalTrials":169,"cells":4894},{"EARLY_PHASE1":4895,"PHASE1":4897,"PHASE2":4899,"PHASE3":4901,"PHASE4":4903,"NA":4905},{"trials":4896,"activeCount":98},[],{"trials":4898,"activeCount":98},[],{"trials":4900,"activeCount":98},[],{"trials":4902,"activeCount":98},[],{"trials":4904,"activeCount":98},[],{"trials":4906,"activeCount":98},[4907],{"nctId":4884,"briefTitle":4885,"status":132,"phases":4908,"primaryCompletion":3129,"completion":4338,"start":4887,"enrollment":713,"conditions":4909,"interventions":4910},[91],[4889,4890],[4869,4892],{"intervention":4912,"totalTrials":169,"cells":4913},"Cinepazide Maleate",{"EARLY_PHASE1":4914,"PHASE1":4916,"PHASE2":4918,"PHASE3":4920,"PHASE4":4922,"NA":4924},{"trials":4915,"activeCount":98},[],{"trials":4917,"activeCount":98},[],{"trials":4919,"activeCount":98},[],{"trials":4921,"activeCount":98},[],{"trials":4923,"activeCount":98},[],{"trials":4925,"activeCount":98},[4926],{"nctId":4927,"briefTitle":4928,"status":870,"phases":4929,"primaryCompletion":4930,"completion":4930,"start":4931,"enrollment":1376,"conditions":4932,"interventions":4934},"NCT04951232","Clinical Study of Cinepazide Maleate Injection in the Treatment of Acute Ischemic Stroke",[91],"2017-01-06","2016-07-04",[4933],"Stroke, Ischemic",[4912],{"intervention":4936,"totalTrials":169,"cells":4937},"Different concentration of ropivacaine for single brachial plexus block",{"EARLY_PHASE1":4938,"PHASE1":4940,"PHASE2":4942,"PHASE3":4944,"PHASE4":4946,"NA":4948},{"trials":4939,"activeCount":98},[],{"trials":4941,"activeCount":98},[],{"trials":4943,"activeCount":98},[],{"trials":4945,"activeCount":98},[],{"trials":4947,"activeCount":98},[],{"trials":4949,"activeCount":98},[4950],{"nctId":4951,"briefTitle":4952,"status":870,"phases":4953,"primaryCompletion":4954,"completion":4954,"start":4955,"enrollment":511,"conditions":4956,"interventions":4960},"NCT06640621","The Effect of Brachial Plexus Block on Diaphragm Movement",[91],"2023-10-07","2022-11-08",[4957,4958,4959],"Phrenic Paralysis","Shoulder Joint Surgery","Rotator Cuff Injury",[4936],{"intervention":4962,"totalTrials":169,"cells":4963},"Dabigatran Etexilate",{"EARLY_PHASE1":4964,"PHASE1":4966,"PHASE2":4968,"PHASE3":4970,"PHASE4":4972,"NA":4974},{"trials":4965,"activeCount":98},[],{"trials":4967,"activeCount":98},[],{"trials":4969,"activeCount":98},[],{"trials":4971,"activeCount":98},[],{"trials":4973,"activeCount":98},[],{"trials":4975,"activeCount":98},[4976],{"nctId":4977,"briefTitle":4978,"status":132,"phases":4979,"primaryCompletion":4980,"completion":53,"start":2610,"enrollment":745,"conditions":4981,"interventions":4983},"NCT06360055","Effect of Oral D-mannose Tablets on Pharmacokinetics of Dabigatranate in Healthy Adults",[91],"2024-11-30",[4982],"Health",[4962],{"intervention":4985,"totalTrials":169,"cells":4986},"Topical Human Granulocyte Macrophage Stimulating Factor Gel",{"EARLY_PHASE1":4987,"PHASE1":4989,"PHASE2":4991,"PHASE3":4993,"PHASE4":4995,"NA":4997},{"trials":4988,"activeCount":98},[],{"trials":4990,"activeCount":98},[],{"trials":4992,"activeCount":98},[],{"trials":4994,"activeCount":98},[],{"trials":4996,"activeCount":98},[],{"trials":4998,"activeCount":98},[4999],{"nctId":5000,"briefTitle":5001,"status":870,"phases":5002,"primaryCompletion":5003,"completion":988,"start":5004,"enrollment":511,"conditions":5005,"interventions":5006},"NCT06608303","Macrophage Stimulating Factor in the Treatment of Diabetic Wounds",[91],"2025-03-12","2024-10-12",[901],[4985,5007],"Saline",{"intervention":5007,"totalTrials":169,"cells":5009},{"EARLY_PHASE1":5010,"PHASE1":5012,"PHASE2":5014,"PHASE3":5016,"PHASE4":5018,"NA":5020},{"trials":5011,"activeCount":98},[],{"trials":5013,"activeCount":98},[],{"trials":5015,"activeCount":98},[],{"trials":5017,"activeCount":98},[],{"trials":5019,"activeCount":98},[],{"trials":5021,"activeCount":98},[5022],{"nctId":5000,"briefTitle":5001,"status":870,"phases":5023,"primaryCompletion":5003,"completion":988,"start":5004,"enrollment":511,"conditions":5024,"interventions":5025},[91],[901],[4985,5007]]